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Abstract 
Mandate of the feasibility study 
The National Programme on HIV and other sexually transmitted infections (STI) 2011-2017 
(NPHS) aims to generate better evidence on the efficiency of its prevention measures for de-
cision-making. The Federal Office of Public Health (FOPH) intends to commission an eco-
nomic evaluation of prevention measures in the field of HIV/STI. This economic evaluation, 
according to the FOPH, should deal with the following topics: 
• The overall cost-benefit-relation of HIV/STI prevention in Switzerland and separately for 
the three axes of intervention of the NPHS. 
• The cost-benefit-relation of the FOPH resources spent for HIV/STI prevention. 
• The optimal allocation of prevention measures (resources) among the three axes of in-
tervention of the NPHS. 
• The cost-benefit-relation of prevention measures for men having sex with men in Zu-
rich. 
Seeking support for the conceptualization of the mandate for such an economic evaluation, 
the FOPH has commissioned the Department of Political Science of the University of Zurich 
to conduct a feasibility study. 
Objectives of the feasibility study 
The feasibility study aims to analyse whether and how an economic evaluation of HIV/STI 
prevention measures can be conducted. It aims to elaborate a concept for a feasible eco-
nomic evaluation. 
Methods of the feasibility study 
In order to define the data requirements for such an economic evaluation, the concept of a 
chain of effects (intervention logic) of the NPHS 2011-2017 is used. The feasibility study 
analyses the state of research in this field and assesses the availability of data. Since data 
on the costs of HIV/STI prevention are largely missing, a pilot study on one selected preven-
tion measure was conducted to generate insights into the feasibility of a cost data collection. 
Further, the feasibility study includes expert interviews and discussions to assess the rele-
vance and the feasibility of such an economic evaluation in Switzerland. Finally, the feasibil-
ity study specifies the mandate for an economic evaluation of prevention measures in the 
field of HIV/STI. 
Findings and recommendations 
Generally, economic evaluation is seen as an instrument to generate policy relevant informa-
tion on the efficient allocation of resources in the field of public health and more narrowly in 
the field of HIV/STI. However, the majority of the studies reviewed here examined single in-
terventions. We found only two analyses dealing with western countries and covering pre-
vention measures of all three intervention axes of the NPHS. Thus, the approach that covers 
multiple prevention interventions as envisaged by the FOPH is not (yet) an established ap-
proach.  
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Cost-utility analyses (using quality-adjusted life years QALY) dominate the field and are most 
frequently conducted from a societal perspective including all costs and consequences of 
HIV/STI prevention. QALY and “infections prevented” were the most commonly used indica-
tors for measuring the effects of HIV/STI prevention interventions. 
The pilot study on the costs of the realisation of a selected measure, “Break the Chain” 2012 
in Zurich, showed that a cost data collection is feasible at a reasonable research effort. How-
ever, the pilot study required a considerable contribution by the actors of "Break the Chain" 
2012. The availability of data on the consequences (outcome/impact) of HIV/STI prevention 
is fragmentary and rather scarce. Surveillance data is available but it does not cover all rele-
vant target populations. Further, data on other STI than HIV is even more limited. 
The expert interviews and discussions reveal that the ambitions of such a study should be 
lowered. The main concerns relate to the difficulties to conceptualise and measure the effec-
tiveness of HIV/STI prevention. The experts share the opinion that the co-operative approach 
adopted in the implementation of the NPHS makes it impossible to reliably estimate the con-
tributions of single actors in terms of achieved consequences. 
In the light of these findings, we formulate the following general recommendations: 
• We recommend dismissing the separate estimation of the efficiency of the resources 
spent for HIV/STI prevention by the FOPH for reasons of feasibility.  
• We recommend not opting for a cost-analysis instead of an economic evaluation of the 
consequences of the NPHS. 
• We recommend that any comparisons of the intervention axes of the NPHS 2011-2017 
should acknowledge the different goals of these axes. 
• We recommend that any comparisons within the intervention axes should take into ac-
count the differences in goals and in the ways of influence of those prevention meas-
ures targeting structural conditions and those directly targeting individual behaviours of 
the end addresses. 
In order to specify the mandate of an economic evaluation we propose two alternatives and 
recommend choosing between them. Alternative A consists in opting for a mathematical 
modelling study that estimates the efficiency of the NPHS and performs scenario analyses 
with respect to the mix of prevention measures. In contrast, alternative B opts for a step-by-
step approach and proposes to start with very restricted but concrete economic evaluations. 
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Zusammenfassung 
Gegenstand der Machbarkeitsstudie 
Das Nationale Programm HIV und andere sexuell übertragbare Infektionen (STI) 2011-2017 
(NPHS) ist bestrebt, für die Entscheidungsfindung bessere Evidenz zur Wirtschaftlichkeit 
seiner Präventionsmassnahmen bereit zu stellen. Vor diesem Hintergrund beabsichtigt das 
Bundesamt für Gesundheit (BAG) eine ökonomische Evaluation der Präventionsmassnah-
men im Bereich HIV/STI in Auftrag zu geben. Gemäss BAG soll diese ökonomische Evalua-
tion folgende Themen abdecken: 
• Kosten-Nutzen-Verhältnis der HIV/STI-Präventionsmassnahmen in der Schweiz insge-
samt sowie separat für die drei Interventionsachsen des NPHS. 
• Kosten-Nutzen-Verhältnis der vom BAG aufgewendeten Ressourcen für die HIV/STI-
Prävention. 
• Optimale Verteilung der Präventionsmassnahmen (Ressourcen) auf die drei Interventi-
onsachsen des NPHS. 
• Kosten-Nutzen-Verhältnis der Zürcher Präventionsmassnahmen für Männer, die Sex 
mit Männern haben (MSM). 
Zur Unterstützung bei der Konzeption des Auftrages (Mandates) für eine solche ökonomi-
sche Evaluation hat das BAG das Institut für Politikwissenschaft der Universität Zürich mit 
der Durchführung einer Machbarkeitsstudie beauftragt. 
Zielsetzung der Machbarkeitsstudie 
Die Machbarkeitsstudie soll untersuchen, ob und inwiefern eine ökonomische Evaluation von 
Massnahmen im Bereich der HIV/STI-Prävention durchgeführt werden kann. Sie soll ein 
Konzept für eine machbare ökonomische Evaluation ausarbeiten. 
Methoden der Machbarkeitsstudie 
Um die Datenbedürfnisse für eine solche ökonomische Evaluation definieren zu können, wird 
das Konzept des Wirkungsmodells (Interventionslogik) des NPHS 2011-2017 verwendet. Die 
Machbarkeitsstudie analysiert den Stand der Forschung auf diesem Gebiet und prüft die Da-
tenverfügbarkeit. Da Daten zu den Kosten der HIV/STI-Prävention weitgehend fehlen, wurde 
eine Pilotstudie zu einer ausgewählten Präventionsmassnahme durchgeführt. Die Pilotstudie 
liefert Erkenntnisse zur Machbarkeit von Kostenerhebungen. Die Machbarkeitsstudie um-
fasst zudem Experteninterviews und -diskussionen zur Relevanz und Machbarkeit einer sol-
chen ökonomischen Evaluation in der Schweiz. Schliesslich konkretisiert die Machbarkeits-
studie das Mandat für eine ökonomische Evaluation von Präventionsmassnahmen im Be-
reich HIV/STI.  
Erkenntnisse und Empfehlungen 
Die ökonomische Evaluation wird grundsätzlich als ein Instrument betrachtet, das erlaubt po-
litikrelevante Informationen über die Effizienz des Ressourceneinsatzes im Gesundheits-
wesen und im engeren Sinne im Bereich HIV/STI zu gewinnen. Die gesichteten Studien un-
tersuchen allerdings meist nur eine einzelne Interventionsmassnahme. Wir fanden nur zwei 
Studien, die sich mit westlichen Ländern befassen und alle drei Interventionsachsen des 
Feasibility study for an economic evaluation of HIV/STI prevention 8 
 
NPHS abdecken. Folglich stellen Analysen, die mehrere Präventionsmassnahmen gemein-
sam untersuchen und damit dem Anliegen des BAG entsprechen, (noch) keine etablierte 
Vorgehensweise dar. 
Kosten-Nutzwert-Analysen, die mit dem Konzept der "qualitätsadjustierten Lebensjahren 
QALY" arbeiten, dominieren die Literatur. Diese Analysen nehmen meistens eine gesell-
schaftliche Perspektive ein und berücksichtigen alle Kosten und Auswirkungen von HIV/STI-
Präventionsmassnahmen. Die am häufigsten verwendeten Indikatoren zur Messung der 
Wirksamkeit der HIV/STI-Präventionsmassnahmen sind die "QALY" und die "verhinderten 
Infektionen". 
Die Pilotstudie zu den Umsetzungskosten einer ausgewählten Massnahme ("Break the 
Chain" 2012 in Zürich) zeigt auf, dass eine Kostenerhebung machbar und mit vernünftigem 
Forschungsaufwand verbunden ist. Allerdings erforderte die Pilotstudie eine beträchtliche 
Beteiligung der Akteure von "Break the Chain" 2012. Es sind nur wenige und lückenhafte Da-
ten zu den Auswirkungen (Outcome/Impact) der HIV/STI-Prävention vorhanden. Daten zur 
Überwachung (Surveillance) von HIV/STI liegen vor, erstrecken sich aber nicht auf alle rele-
vanten Zielgruppen. Die Datengrundlagen zu den anderen STI sind noch spärlicher als die 
Daten im Zusammenhang mit HIV.  
Die Experteninterviews und -diskussionen zeigen auf, dass die Zielsetzungen einer solchen 
Studie herabgesetzt werden sollten. Die grösste Schwierigkeit sei, die Wirksamkeit von 
HIV/STI-Präventionsmassnahmen zu konzeptualisieren und zu messen. Die Expertinnen und 
Experten sind sich einig, dass eine zuverlässige Einschätzung des Beitrags einzelner Akteu-
re an der Zielerreichung des NPHS aufgrund der kooperativen Umsetzung des NPHS nicht 
möglich ist. 
Angesichts dieser Erkenntnisse formulieren wir folgende Empfehlungen: 
• Aus Gründen der Machbarkeit empfehlen wir, auf eine separate Beurteilung der Wirt-
schaftlichkeit des Ressourceneinsatzes des BAG für die HIV/STI-Prävention zu ver-
zichten.  
• Ebenfalls sollte darauf verzichtet werden, anstelle einer ökonomischen Evaluation der 
Auswirkungen des NPHS eine Kostenanalyse durchzuführen.  
• Wir empfehlen, dass bei Vergleichen zwischen den Interventionsachsen des NPHS 
2011-2017 den unterschiedlichen Zielsetzungen dieser Achsen Rechnung getragen 
wird. 
• Bei Vergleichen innerhalb der Interventionsachsen sollte berücksichtigt werden, dass 
Massnahmen, welche strukturelle Bedingungen im Fokus haben und Massnahmen, die 
direkt auf die individuellen Verhaltensweisen der Endadressatinnen und -adressaten 
von Präventionskampagnen abzielen, unterschiedliche Ziele verfolgen und auf unter-
schiedlichen Wirkungsketten basieren. 
Zur Konkretisierung des Mandats für eine ökonomische Evaluation schlagen wir zwei Varian-
ten zur Auswahl vor: Variante A sieht eine mathematische Modellierung zur Schätzung der 
Wirtschaftlichkeit des NPHS vor und umfasst Szenario-Analysen zum Massnahmenmix. Va-
riante B sieht ein schrittweises Vorgehen vor und empfiehlt, mit eng fokussierten, konkreten 
ökonomischen Evaluationen zu beginnen.  
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Résumé 
Mandat de l’étude de faisabilité 
Le Programme national VIH et autres infections sexuellement transmissibles (IST) 2011–
2017 (PNVI) vise à fournir de meilleures données scientifiques sur l’efficience des mesures 
de prévention qu’il contient en vue des futures décisions à prendre. L’Office fédéral de la 
santé publique (OFSP) prévoit de mandater une évaluation économique des mesures de 
prévention dans le domaine VIH/IST, qui porterait sur les thèmes suivants : 
• Rapport coûts-bénéfices de l'ensemble de la prévention VIH/IST en Suisse d'une part 
et de chacun des trois axes d'intervention du PNVI d'autre part. 
• Rapport coûts-bénéfices des fonds de l’OFSP dépensés en faveur de la prévention 
VIH/IST. 
• Répartition optimale des mesures de prévention (fonds) entre les trois axes 
d’intervention du PNVI. 
• Rapport coûts-bénéfices des mesures de prévention ciblant les hommes ayant des 
rapports sexuels avec d’autres hommes à Zurich. 
En vue de la définition du mandat d’une telle évaluation économique, l’OFSP a chargé 
l’Institut de science politique de l’Université de Zurich de réaliser une étude de faisabilité. 
Objectifs de l’étude de faisabilité 
L’étude de faisabilité vise à déterminer dans quelle mesure il est possible de mener une étu-
de économique des mesures de prévention dans le domaine VIH/IST. Elle a également pour 
objectif de préciser le concept d’une éventuelle évaluation économique. 
Méthodes de l’étude de faisabilité 
Afin d'établir quelles données sont nécessaires à une telle étude économique, les mandatai-
res utilisent le concept d’une chaîne d’effets (logique d’intervention) du PNVI 2011-2017. 
L’étude de faisabilité analyse l’état de la recherche dans ce domaine et examine la disponibi-
lité des données. Comme les données relatives aux coûts de la prévention dans le domaine 
VIH/IST font largement défaut, une étude pilote a été menée avec une mesure de prévention 
donnée afin de générer un aperçu de la faisabilité d’une collecte de données. Par ailleurs, 
l’étude de faisabilité englobe des interviews et des discussions avec des experts afin de dé-
terminer la pertinence et la faisabilité d’une évaluation économique dans ce domaine en 
Suisse. Enfin, elle précise le mandat d’une évaluation économique des mesures de préven-
tion dans le domaine VIH/IST. 
Conclusions et recommandations 
De manière générale, les évaluations économiques sont considérées comme un instrument 
permettant de générer des informations déterminantes pour les décisions politiques en ce 
qui concerne l’octroi des fonds dans le domaine de la santé publique, et plus précisément 
dans celui du VIH/IST. Toutefois, la majorité des études menées dans ce domaine portent 
sur des interventions uniques. Nous n’avons trouvé que deux études traitant des pays occi-
dentaux et englobant des mesures de prévention pour les trois axes d’intervention du PNVI. 
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Par conséquent, l’approche envisagée par l’OFSP consistant à couvrir plusieurs axes pour 
les mesures de prévention, n’est pas (encore) une approche établie.  
Les analyses coûts-utilité (en utilisant le paramètre « Quality Adjusted Life Year QALY »; an-
née de vie ajustée par la qualité) sont très présentes dans ce domaine et sont le plus sou-
vent menées dans une perspective sociétale incluant l’ensemble des coûts et des consé-
quences de la prévention VIH/IST. Les indicateurs « QALY » et « infections évitées » sont 
les indicateurs les plus souvent utilisés pour mesurer les effets des mesures de prévention 
dans le domaine VIH/IST. 
L’étude pilote relative aux coûts de la mise en œuvre d'une mesure sélectionnée (« Break 
the Chain » 2012 à Zurich) a montré qu’il est possible d’obtenir des données moyennant un 
effort de recherche raisonnable. Toutefois, elle a nécessité une très forte participation de la 
part des acteurs de « Break the Chain » 2012. Les données sur les conséquences (outcome/ 
impact) de la prévention dans le domaine VIH/IST sont incomplètes et plutôt rares. Des don-
nées de surveillance sont certes disponibles, mais elles ne couvrent pas l’ensemble des 
groupes cibles. De plus, les données relatives aux IST autres que le VIH sont encore plus 
rares. 
Il ressort des interviews et des discussions avec les experts qu’il faudrait réduire les ambi-
tions concernant une étude économique dans ce domaine. La principale préoccupation mise 
en avant concerne la difficulté à conceptualiser et à mesurer l’efficacité de la prévention dans 
le domaine VIH/IST. Les experts sont unanimes sur le fait que l’approche coopérative adop-
tée lors de la mise en œuvre du PNVI rend impossible une estimation fiable des contribu-
tions fournies par les différents acteurs en termes d'objectifs atteints. 
A la lumière de ces conclusions, nous émettons les recommandations générales suivantes: 
• Pour des raisons de faisabilité, nous recommandons de renoncer à une estimation sé-
parée de l’efficience des fonds dépensés par l’OFSP en faveur de la prévention dans le 
domaine VIH/IST.  
• Nous recommandons de renoncer à une analyse des coûts et de maintenir une étude 
économique sur les conséquences du PNVI. 
• Nous recommandons que toute comparaison entre les axes d’intervention du PNVI 
2011-2017 considère les différents objectifs de ces axes. 
• Nous recommandons que toute comparaison au sein des axes d’intervention tienne 
compte des différences d’objectifs et de sphères d'influence entre les mesures de pré-
vention portant sur des conditions structurelles et celles visant directement le compor-
tement individuel des destinataires finaux. 
Afin de préciser le mandat d’une évaluation économique, nous proposons deux variantes et 
recommandons au mandant de choisir entre les deux. La proposition A consiste à opter pour 
une étude reposant sur un modèle mathématique qui estime l’efficience du PNVI et qui effec-
tue des analyses de scénarios en tenant compte des différentes mesures de prévention. A 
l’inverse, la proposition B consiste à opter pour une approche pas à pas et propose de com-
mencer par des évaluations économiques très limitées mais concrètes. 
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1 Introduction 
1.1  Background: The need of the Federal Office of Public Health for an eco-
nomic evaluation in the field of HIV/STI prevention 
The National Programme on HIV and other sexually transmitted infections (STI) (NPHS) 
2011-2017 aims to generate better evidence on the efficiency of its prevention measures for 
decision-making (Federal Office of Public Health, 2010: 114). Several studies stated the lack 
of evidence on the costs of HIV/STI prevention as well as on the cost-effectiveness of 
HIV/STI prevention in Switzerland (Dubois-Arber et al. 2012: 14; Erne et al. 2010: 12-15; 
Frey/Kübler 2011: 12-13; Neuenschwander/Kübler 2006). 
The Federal Office of Public Health (FOPH) intends to commission an economic evaluation 
of prevention measures in the field of HIV and other STI. This economic evaluation, should 
aim to generate evidence on the following topics:1
• The overall cost-benefit-relation of HIV/STI prevention in Switzerland and separately 
for the three axes of intervention of the NPHS: 1. General population, 2. People with a 
higher risk of exposure, 3. Infected individuals and their partners.
 
2
• The analysis should focus on the FOPH resources spent for HIV/STI prevention sepa-
rately as well as include all resources (cantonal, communal, public and private) spent 
on HIV/STI prevention in Switzerland. 
  
• The optimal allocation of prevention measures (resources) among the three axes of 
intervention of the NPHS.  
• The cost-benefit-relation of prevention measures for MSM in Zurich. 
Further, the study should be conducted in a societal perspective and take into account that 
the regions (cantons) of Switzerland are differently affected by HIV and other STI. 
Seeking support for the specification of the mandate for this economic evaluation, the FOPH 
has commissioned the Department of Political Science of the University of Zurich (Prof. Dr. 
Daniel Kübler) to conduct a feasibility study for such an economic evaluation. This feasibility 
study was executed in the period from August 2012 to Mai 2013. The present document re-
ports on the results of this feasibility study and outlines recommendations for the definition of 
a mandate for an economic evaluation on behalf of the FOPH. 
1.2  Aim and questions of the feasibility study 
The aim of the present feasibility study is to analyse, whether and how an economic evalua-
tion of HIV/STI prevention measures can be conducted. The feasibility study provides the 
scientific bases for the discussions and decisions concerning the realisation and conceptuali-
sation of an economic evaluation of Swiss HIV/STI prevention measures. On the one hand, 
the present study aims to contribute to a common understanding of conceptual issues as well 
                                               
1  The FOPH has specified these topics in a meeting in June 2012 and defined them in the evaluation requirements (Pfichten-
heft) of the present feasibility study. 
2  The NPHS 2011-2017 groups HIV and STI measures into three axes that are directed to specific target populations, namely 
the general population, the people with a higher risk of exposure and infected individuals and their partners (FOPH 2010: 
83). We introduce these axes in section 3. 
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as to shared expectations on potential findings of an economic evaluation in this field. On the 
other hand, it aims to elaborate a concept for a feasible economic evaluation. 
The feasibility study seeks to answer the following questions: 
1. What is the scientific state of the art in this field? How are costs, effects, utilities and 
benefits conceived? Which indicators and methods are used in economic evaluations 
of HIV/STI prevention? 
2. Which data and data sources are available on the costs (efforts, resources) spent for 
HIV/STI prevention? Which secondary analyses are possible? Necessity and possi-
bilities of primary data collection? 
3. Which data and data sources are available on the effects, utilities and benefits of 
HIV/STI prevention in Switzerland? Which is the potential of secondary analyses? 
Necessity and possibilities of primary data collection? 
4. What are the implications and challenges for an economic evaluation of HIV/STI pre-
vention in Switzerland? 
5. Which HIV/STI prevention interventions should be considered in an economic evalua-
tion (considering that implementation efforts can differ at the local level)? 
6. How should a feasible economic evaluation be designed (study design, methods, in-
dicators, data sources)? 
1.3  Methods of the feasibility study 
We structured the present report into nine sections. Table 1 presents an overview of the 
questions addressed and methods used in each section. 
In the next section 2, we define the core concepts of an economic evaluation that are used 
thereafter consistently throughout this report. In section 3, we elaborate a chain of effects of 
the NPHS 2011-2017. Such a chain of effects systematizes and maps the causal framework 
(intervention logic) of an evaluation object.  
In section 4, we analyse the current state of the art. It contains a review of the international 
literature on economic evaluations of HIV/STI prevention interventions, as well as an analysis 
of the Swiss literature and the current practice of international organizations (WHO, UNAIDS, 
OECD, ECDC, CDC), focussing on cost analyses and economic evaluations dealing with 
health promotion and prevention. 
Thereafter, we present the findings on the availability of data, assess the feasibility of secon-
dary data analyses and discuss the requirement of field research (section 5). Section 6 pre-
sents the results of a pilot study that was conducted to generate insights into the feasibility of 
the collection of cost data since such data is largely missing in Switzerland.  
Sections 7 and 8 present experts’ assessments of the relevance and the feasibility of an 
economic evaluation in the field of HIV/STI prevention in Switzerland. On the one hand, we 
discussed the feasibility study with the Surveillance Working Group of the Federal Commis-
sion for Sexual Health (FCSH). On the other hand, we conducted five in-depth interviews 
with health economists. 
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Finally, the findings of the sections 2 to 8 are synthesised and used to concretise a feasible 
concept for an economic evaluation in the field of HIV/STI prevention (section 9). 
 
Table 1: Overview on the structure and methods of the feasibility study 
Section Question Topics Method / Data sources 
 1 2 3 4 5 6   
1       Introduction: Aim, methods, question of 
the present feasibility study. 
 
2       Conceptual issues of an economic 
evaluation of HIV/STI prevention 
Qualitative (literature review) 
3       Elaboration of the chain of effects of the 
NPHS 2011-2017 
Qualitative (document analysis, literature 
review) 
Programme documentation of the NPHS 
2011-17. 
4       Current practice of relevant interna-
tional organisations and state of the art 
in the literature. 
Qualitative (document analysis) 
Quantitative (literature analysis) 
Websites, databases, the literature analy-
sis on economic evaluation of HIV/STI pre-
vention includes 108 articles. 
5       Data availability, necessity and possi-
bilities of secondary data analyses and 
primary data collection. 
Databases such as the Swiss HIV Cohort 
Study, surveillance data, etc. 
 
6       Pilot study: Collection of data on the 
prevention costs of Break The Chain 
(BTC) in Zurich 2012. 
Qualitative (document analysis) 
Quantitative (cost data collection) 
Documents of BTC, financial data, estima-
tions provided by the involved actors. 
7       Assessment by the Surveillance Work-
ing Group of the FCSH. 
Presentation and discussion with the Sur-
veillance Workings Group. 
8       Expert assessment of the relevance 
and feasibility of an economic evalua-
tion in the field of HIV/STI in Switzer-
land. 
Qualitative (expert interviews) 
Five guideline based interviews with ex-
perts of economic evaluation in the field of 
public health. 
9       Concretisation of a concept for an eco-
nomic evaluation of HIV/STI prevention 
Qualitative (synthesis) Findings of  the pre-
sent feasibility study 
Dark cells: Sections provide main results for the respective questions. 
More details on the methods and data sources are provided in the respective sections. 
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2 Conceptual issues of an economic evaluation 
An economic evaluation of a prevention measure aims to answer the question "is it worth it?" 
and thus, compares the costs of the measure (intervention, programme or policy) with its 
consequences. In other words, an economic evaluation provides information on the efficiency 
of a prevention measure. It requires data on the input (costs of the measure) as well as on 
the effectiveness of the respective measure. Economic evaluation is used here as an um-
brella term. 
In the following we outline the conceptual issues of an economic evaluation in the field of 
HIV/STI prevention. We introduce the types of analyses, explain how costs and benefits are 
differentiated in the literature and highlight the perspectives of analysis. 
2.1  Types of analyses 
In general, the evaluation literature distinguishes in the economic evaluation domain between 
costs (or productivity) analyses and efficiency analyses (Levin et al. 2001; Widmer/De Rocchi 
2012: 52; Drummond et al. 2005: 11; Telser/Zweifel 2000: 4-7). The former concentrates on 
the analysis of the costs of a measure (or any public goods and services) and often aims at 
comparing the costs of alternative measures. However, this type of economic information 
does not provide any insights whether a measure was worth its costs. The latter type of 
analysis sets the costs of a measure in relation to its consequences (or results). This type of 
analysis is of particular relevance for the present feasibility study.  
The literature on economic evaluation in the field of public health usually differentiates be-
tween three types of efficiency analyses (Drummond et al. 2005: 11; Gutzwiller et al. 2012: 
16-27; Iten et al. 2009: 13-14; Schmiedhauser et al. 2009: 14-15).3
• A cost-effectiveness analysis (CEA, Kosten-Wirksamkeit-Analyse) concentrates on the 
generic effects of prevention interventions measured in natural units (e.g. the number 
of infections averted, years of life gained, decrease in risk behaviour). These effects 
can comprise intended and not-intended, intermediate or ultimate changes attributable 
to a prevention intervention.  
 These types differ in the 
way they measure the consequences of an intervention (see Table 2). In the present study, 
the term "consequences of a prevention intervention" includes all type of effects, utilities or 
benefits. In the literature, the term "outcome" is often used alternatively. Instead, outcome is 
used in the present study for a particular type of effects accordingly to the chain of effects (in-
tervention logic) of an intervention (see section 3). 
• A cost-utility analysis (CUA, Kosten-Nutzwert-Analyse) measures the consequences 
of an intervention with an utility index. This type of analysis measures the utility of a 
particular health state (health improvement attributable to the prevention intervention). 
In other words, utilities aim to reflect the worth of a particular prevention effect for an 
individual or for the society; how much utility does an increase in life have when it is 
accompanied by pain or disability? Utilities include a measurement of health state 
preferences by the population and/or the target population of the intervention. They 
combine various disparate health effects of an intervention into a single composite util-
                                               
3  Some authors further introduce the cost-minimization analysis as an individual type of efficiency analyses (Widmer/De Roc-
chi 2012). Cost-minimization analyses aim to identify the most cost-efficient way to cause certain consequences. 
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ity score (Drummond et al. 2005: 137-209; Gutzwiller et al. 2012: 18-27). The conven-
tional approach uses the concept of quality-adjusted life years QALY (Schöff-
ski/Greiner 2008). This approach weighs the years of life saved with a utility score that 
reflects the preferences of the affected people for a particular health state (combina-
tion of life quantity gains and life quality gains). An alternative approach developed by 
the WHO is the concept of disability-adjusted life years (DALY) (Schmiedhauser et al. 
2010: 24-25; Wieser et al. 2010: 8). DALY are computed by adjusting age-specific life 
expectancy for the loss of healthy life due to a disability and are based on experts' 
judgements. 
• Cost-benefit analysis (CBA, Kosten-Nutzen-Analyse) translates costs and conse-
quences into the same metric, namely a monetary value. The relation between these 
two variables can be expressed in a simple term, such as the cost-benefit ratio. Thus, 
the benefit expresses the consequences of a prevention intervention as a monetary 
value. 
Table 2: Types of economic evaluation (e.g. based on Drummond et al. 2005). 
Type of economic evaluation Measure of costs (resources and 
money spent for prevention) 
Measure of consequences 
Cost-effectiveness analysis Money Effects / natural units 
(e.g. averted HIV/STI infections, life year 
gains, improvement of sexual health) 
Cost-utility analysis Money Health utilities 
Integrated measures for health utilities 
such as QALYs quality adjusted life years 
gained or DALYs disability adjusted life 
years gained 
Cost-benefit analysis Money Money; benefit expresses the monetary 
value of the consequences 
 
2.2  Categories of costs and benefits 
Economic evaluations in the field of public health usually refer explicitly or implicitly to three 
broad categories of costs and benefits (e.g. Drummond et al. 2005: 24; Zurn et al. 2001: 16-
17; Iten et al. 2009: 15-17). These categories include the direct, the indirect and the intangi-
ble costs and benefits. Direct costs and benefits include all costs spent or avoided by a pre-
vention intervention. Indirect costs and benefits cover any changes in productivity attributable 
to a prevention intervention. Intangible costs and benefits stand for any suffering or utility 
changes attributable to a prevention intervention. Table 3 provides an overview and concre-
tises the categories for the case of HIV/STI prevention. 
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Table 3: Costs and benefits of HIV/STI prevention measures 
 Costs (money spent for prevention) Benefits (monetary value of the consequences) 
Direct Direct costs of the prevention measures 
• Personnel, material, overhead and capital costs 
spent for the implementation of the HIV/STI pre-
vention measure. 
Averted direct costs 
• Treatment costs saved by the prevention of new 
HIV/STI infections. 
• Savings of other sectors 
Indirect Productivity losses due to the participation in the pre-
vention measure 
• Time of volunteers as well as respective trans-
port costs spent to implement and support the 
HIV/STI prevention measure. 
• Time and transport costs of the target population 
for their participation in the HIV/STI prevention 
measure. 
Productivity gains due to the improved health status of 
the population 
• Productivity gains due to the improvement of 
sexual health/averted HIV/STI infection (reduced 
costs of morbidity/mortality). 
• Productivity savings in volunteers' and relatives' 
work time and transport costs. 
Intangible Utility losses attributable the prevention measures 
• Loss of (sexual) pleasure caused by the HIV/STI 
prevention measure. 
• Other intangible costs 
Increase in duration and quality of life 
Iten et al. (2009: 17) or Schmiedhauser et al. (2009: 15) use similar schemes. Here, we specified the costs and benefits with 
respect to HIV/STI prevention measures.  
 
These categories of costs and benefits rely on the possibility of quantification and monetiza-
tion of prevention effects. This might be possible for some inputs and consequences of a 
prevention intervention but hardly for all. On the one hand the literature provides different 
approaches to quantification and monetisation (e.g. for the estimation of productivity gains or 
the measurement of intangible costs or benefits). On the other hand, economic evaluations 
often omit some categories. The present study will highlight how the current literature on 
economic evaluation in the field of HIV/STI deals with these challenges. 
Furthermore, Table 3 omits one type of costs that is very much disputed in the literature on 
economic evaluation in the field of public health, namely the unrelated costs. As prevention 
measures aim to improve public health, people might live longer and this might result in "ad-
ditional" costs of health care or of other sectors (e.g. Drummond et al. 2005: 62-64; Iten et al. 
2009: 17-18). We omit this type of costs in accordance with the current state of the art. 
2.3  Perspectives of the analyses 
An economic evaluation can be conducted from different perspectives with respect to who 
pays for and who benefits from a prevention intervention (Drummond et al. 2005: 17-22). 
While a societal perspective includes all costs and consequences of HIV/STI prevention 
measures, no matter who pays or benefits (including the public and private sector as well as 
the consumers), the health provider and public sector perspective omit some types of costs. 
The health provider perspective omits the costs and benefits incurred by private consumers 
(such as participants' time or travel costs). The public sector perspective excludes both the 
private sector and the private consumers and includes only costs incurred by the public sec-
tor in implementing a prevention measure. 
Thus, the perspective defines whose costs and benefits are to be included in an economic 
evaluation. Choosing the societal perspective for the economic evaluation to be commis-
sioned, the FOPH has opted for the most comprehensive perspective that includes all costs 
and benefits no matter who pays or benefits. 
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3 The intervention logic of the NPHS 2011-2017 
In this section we first provide an overview on the epidemiological trends as well as a short 
outline of the NPHS 2013. Second, we present the chain of effects of the NPHS 2011-2017. 
This analytical tool shows how the programme is thought to work and thereby indicates the 
data requirements for an economic evaluation of its prevention measures. 
3.1  Epidemiological trends in a nutshell 
Recent epidemiological trends for Switzerland show that there is no relief in sight for HIV and 
other STI: The number of reported HIV and other STI cases increased in 2012 (FOPH 2012c: 
910). While HIV reports declined between 2007 and 2011 from 759 to 564 cases, the FOPH 
expects an increase of 3-8% of reported HIV diagnoses in 2012 compared to 2011. The 
FOPH estimates the total number of reported HIV diagnoses to 610 in 2012. The reported 
number of syphilis, gonorrhoea and chlamydia diagnoses increased considerably in the last 
years. 
There are two core observations that direct HIV and STI policy in Switzerland, namely that 
the population and Swiss regions are not evenly affected by HIV and other STI (FOPH 
2012c: 911). Most affected are men having sex with men (MSM) (FOPH 2012a: 1). Forty-five 
per cent (nearly 260) of the HIV diagnoses reported in 2011 originated from this group. Fur-
ther, migrants from countries with a high HIV prevalence, as well as injecting drug users 
(IDU) are considerably affected by HIV. 
The prevalence of HIV and STI varies depending on where people live: large urban centers 
such as the cities of Zurich, Lausanne, Bern, Geneva and Basel are affected the most 
(FOPH 2012a: 7). The Swiss cantons can be classified into three groups: Most affected are 
Zurich, Geneva and Vaud, while Basel, Bern, Luzern, St. Gallen and Ticino are moderately 
affected, and all other cantons are little affected by the HIV and STI epidemics (FOPH 
2012b: 7, 11-13, 16). 
3.2  NPHS 2011-2017: Goals and intervention axes 
The NPHS 2011-2017 is the Swiss national strategy not only for prevention but also for the 
diagnosis and treatment of HIV and other STI. Its overall goal is to improve the sexual health 
of the Swiss population (FOPH 2010: 7). More precisely, it formulates four main goals (the 
following bullet points comprise excerpts from the programme, ibid. 77-79): 
• People living in Switzerland are informed, educated and capable of exercising their 
rights with regard to sexuality. 
• A decrease in the risk of transmission of HIV and other STI. 
• Early detection and correct treatment of HIV and other STI. 
• The impact of efforts related to HIV and STI is sustained, because it relies on target 
group participation, is based on scientific evidence and is supported by the population. 
The NPHS structures the HIV and STI interventions along three “axes of intervention” (FOPH 
2010: 7, 83-85). These three axes address particular population groups. The division into 
axes is based on the criteria of prevalence and vulnerability (risk): 
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• Intervention axis 1 targets everyone living in Switzerland (general population) and in 
particular teenagers, young men and women, Migrants from countries without a gen-
eralised epidemic, clients of sex workers and travellers to countries with an epidemic 
prevalence of HIV/STI. 
• Intervention axis 2 targets sexually active individuals with an increased risk of expo-
sure to HIV and/or STI. These risk groups are men who have sex with men (MSM), 
migrants form countries with a generalised epidemic, sex workers, injecting drug users 
(IDU) and prison inmates.  
• Intervention axis 3 targets individuals with HIV and/or a STI as well as their partners.  
Although all three axes comprise prevention of HIV/STI, its emphases differ: For the general 
population (axis 1) the emphasis is placed on measures aiming to raise the awareness to the 
value of sexual health. While the emphasis is placed on prevention for people with increased 
risk (axis 2), for infected persons and their partner (axis 3), the focus is on diagnosis, coun-
selling and therapy. The NPHS defines particular aims, measures and responsibilities for 
each intervention axis. 
The FOPH implements this programme in collaboration with many partners, including can-
tonal and communal authorities as well as non-governmental organisations. 
3.3  Focus of the feasibility study: Prevention measures 
While the NPHS is a comprehensive strategy, the feasibility study focuses on HIV/STI pre-
vention measures. Preventive interventions or measures aim to reduce the occurrence, 
spread and negative effect of these infections. In this feasibility study, we concentrate on be-
havioural prevention that targets directly individuals as well as structural/contextual preven-
tion that aims to improve relevant social contexts (e.g. risk settings, legislation). Prevention 
interventions that focus on early detections of these infections (testing, screening) are also 
included. As the FOPH aims to generate evidence on all three intervention axes, so called 
positive prevention (Rosenbrock et al. 2009: 25-27) that targets infected people and their 
partners and aims to reduce the transmission of the infections is also included. We excluded 
medical prevention interventions such as mother-to child HIV transmission or pre- and post-
exposure-prophylaxis. 
3.4  Intervention logic of the preventions measures of the NPHS 2011-2017 
The information requirements of an economic evaluation can be illustrated by the concept of 
the chain of effects (Wirkungsmodell, intervention logic, program theory) that is broadly used 
in policy analysis and evaluation (Chen 2005: 34-38; Frey/Widmer 2011: 496-7; Mohr 1995; 
Widmer/Frey 2006: 292-4; Mauch/Balthasar 2007: 9). A chain of effects systematises and 
maps the causal framework of an evaluation object such as the NPHS or its individual meas-
ures (e.g. intervention axes, campaigns, projects). In other words, it shows how a pro-
gramme is thought to work. We distinguish between the five stages of input, process, output, 
outcome and impact (see Figure 1). Input stands for the costs of both the programme itself 
and its implementation. Whereas output covers products and services provided directly by a 
programme and directed toward its immediate addressees, outcome covers the effects of the 
programme on its addressees. In contrast to outcome, impact stands for the effects on par-
ties other than those directly addressed, or in other words, on people beyond the immediate 
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addressees. The benefit of a prevention programme is not included as a distinct stage in 
Figure 1 as it stands for the monetization of its consequences and therefore can relate to all 
or only to particular consequences at the impact or outcome stage. Figure 1 aims to be as 
simple as possible to illustrate the basic logic of a chain of effects and therefore, we did not 
insert the benefit as additional layer. 
We elaborated a chain of effects that systematises the intervention logic of the NPHS for the 
purpose of an economic evaluation. On the one hand, this chain of effects is based on the 
programme documentation (FOPH 2010) and a report of the Swiss Aids Federation (AHS) 
that elaborates the chains of effects (Wirkungsmodelle) for the prevention its programmes of 
the AHS (Ackermann 2012). On the other hand, it is based on our analysis of the interna-
tional literature on economic evaluation of HIV/STI prevention and on the more general litera-
ture on economic evaluation in the field of public health (e.g. Drummond et al. 2005: 19). 
We present the chain of effects from the perspective of the FOPH as it is responsible for 
managing and coordinating the formulation, implementation and evaluation of the NPHS 
2011-17 (FOPH 2010: 129). The FOPH aims to lead HIV/STI prevention in the directions of 
the NPHS 2011-17. Therefore, output stands for FOPH's services and products of the NPHS 
(see Figure 1). Partner organizations (e.g. Swiss Aids Federation, cantons) as well as target 
populations (e.g. general population, men having sex with men, migrants, sex workers) are 
considered as the addressees of the FOPH's services and products. Their implementation 
efforts and behaviour changes are attributed to the outcome (green box). The impact stands 
for the broader effects of NPHS 2011-17 at the level of the society. Figure 1 illustrates the 
basic logic of a chain of effects in a multilevel setting. It is kept as simple as possible and 
does neither display all involved partners nor specify the levels. It shows that FOPH as well 
as its partner institutions invest resources to implement the NHPS 2011-17 (red boxes).  
Figure 1: Chain of effects in a multilevel setting (Widmer/Frey 2006: 293) 
 
This basic model of a chain of effects needs some adaptation for the purpose of an economic 
evaluation, in particular for a CBA conducted in a societal perspective that aims to cover all 
costs and benefits regardless who pays or benefits. In our opinion, such a model needs to 
depict all categories of costs and benefits of HIV/STI prevention as defined in Table 3. Both, 
costs and benefits can occur at different stages of the chain of effects. In the literature, the 
costs are usually depicted at the beginning and the benefits at the end of a chain of effects 
(e.g. Mauch/Balthasar: 9, Frey et al. 2012: 27).  
In the following, we define the stages of the chain of effects of the NPHS 2011-17 in a gen-
eral way (Figure 2). This chain of effects does not display full details (such as concrete cam-
paigns, intervention projects, outcomes among particular target groups) but defines the 
broad categories that can be modified for any particular area of intervention such as the 
Input Process (P) Output Outcome Impact 
Outcome Input P Output Impact 
FOPH 
P Outcome Impact Output 
Swiss Aids Federation 
Local aids help organisation P Output Outcome 
Cantonal or local authority Input 
Input Impact 
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three axes of the NPHS 2011-17. Figure 2 displays all stages relevant for an economic 
evaluation. The stages are specified either according to information obtained from the pro-
gramme document (FOPH 2010) or by an adaptation of insights from the literature on eco-
nomic evaluation (see in particular Iten et al. 2009: 15-18, Schmiedhauser et al. 2009; 15-19, 
Drummond et al. 2005: 19). We omitted the process stage as it is not of primary interest for 
an economic evaluation that focuses on the consequences of HIV/STI prevention. We depict 
the input in a separate box on the left edge while the benefit (monetization of the conse-
quences) is displayed in a separate box at the right edge of Figure 2. We opted for this de-
lineation for analytical reasons (see next paragraph), even though the input partially accrues 
on the outcome stage (costs that are borne by the partners and end-addresses of the 
NPHS). This also holds true for the benefit that stands for the monetization of the conse-
quences of the NPHS that can occur at the outcome or impact stage of the chain of effects. 
As introduced in section 2.2, we distinguish between direct, indirect and intangible costs and 
benefits (see Table 3, Iten et al. 2009: 17; Schmiedhauser et al. 2009:15). 
In this way, the relations between input and the consequences can be easily identified. The 
relation between input and output only assesses the productivity of the FOPH's activities re-
lated to the NPHS. The longer the causal chain covered by the relation of interest, the more 
complex the analysis gets and the more uncertainties are to consider. While CBA relates in-
put to benefits, CEA can either relate input to outcome or impact.  
We would like to emphasize that this model serves the reduction of the complexity of the re-
ality for the purpose of an economic evaluation. We aimed to include the categories of costs 
and benefit discussed in the literature on economic evaluation (e.g. Iten et al. 2009: 15-18; 
Schmiedhauser et al. 2009: 15, 17, 19). Some of these categories, in particular the intangible 
costs, are difficult to detect and might not be of great relevance for (some) HIV/STI preven-
tion measures. 
 
 Figure 2: Chain of effects of the NPHS 2011-17, general intervention logic 
 
 
 
 
Input Intended outcome 
Indirect costs 
Resources (e.g. 
time) spent by the 
voluntary sector, 
participants of the 
prevention inter-
ventions and their 
relatives 
Direct costs 
Resources spent 
by the FOPH and 
its public and pri-
vate partners at 
the federal, can-
tonal, communal 
levels 
Intangible costs 
 
Suffering/ utilities 
losses of the par-
ticipants 
Output 
FOPH 
 
Activities 
related to 
the NPHS 
2011-2017 
Improvement of structural condi-
tions that support/empower inhabi-
tants to exercise sexual rights and 
maintain/improve their sexual health 
Behaviour changes among the 
partners/ multipliers 
Maintain/increase their contributions 
to HIV/STI prevention. 
Behaviour changes 
among end addressees 
(targeted populations) 
Changes of awareness, 
knowledge, cognitions, 
and behaviours 
Increase low-risk sexual 
behaviour 
Improve testing/ vaccina-
tion behaviour 
Intended impact 
Public health improve-
ments 
Less HIV/STI infections 
Less unwanted pregnancies 
Improved sexual health 
Increase of quality of life in 
terms of health and life ex-
pectancy (less suffering) 
Lower morbidity and prema-
ture mortality 
Direct benefits 
Health care savings 
Saving in other sectors 
Indirect benefits 
Savings of resources of 
patients, relatives and 
volunteers 
Productivity gains 
Intended benefit  
Intangible benefits 
Monetisation of health 
improvements including 
the quality of life (will-
ingness-to-pay) 
Unintended changes of structural 
conditions 
Unintended behaviour changes 
among the partners/multipliers 
Other, unintended behav-
iour changes among end 
addressees (targeted 
populations) 
Changes of awareness, 
knowledge, cognitions, 
and behaviours 
Other, unintended effects at 
the level of the society 
Other, unintended (di-
rect, indirect, intangible) 
benefits or losses 
Unintended outcome 
Unintended impact Unintended benefit 
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In the following, we describe the individual stages of the chain of effects displayed in Figure 2 
in detail. Thereby, we concentrate on the intended consequences of the stages of the chain 
of effects. However, it is important to consider that the NPHS might cause unintended con-
sequences. Unintended consequences are understood as a broad category of consequences 
that are not covered by the goals of the NPHS. Such unintended consequences can be 
known or unknown (anticipated or not-anticipated), negative or positive. An economic evalua-
tion of HIV/STI prevention measures has to consider these unintended consequences. 
Input: The input comprises all resources spent for the implementation of the NPHS. The 
FOPH wants the allocation of resources to reflect the epidemiological develop-
ments and to be based on evidence of the effectiveness and efficiency of the inter-
ventions (FOPH 2010). A societal perspective includes the resources spent by all 
involved public or private actors for the formulation, realisation (implementation) as 
well as evaluation of the NPHS 2011-2017. Various public and private actors at the 
federal, cantonal and communal levels are involved in these "spending processes" 
that are to consider in any cost data collection. 
Direct costs are important for all prevention measures of the NPHS. They can vary 
not only with respect to the amounts and relevance of subcategories (see Table 3) 
but also with respect to the actors and sectors involved in the implementation of 
individual measures. For example, prevention measures of axis 1 involve the edu-
cation sector and its actors, while prevention interventions of axis 2 rely on the ef-
forts of non-governmental organisations and can also include social services.  
Indirect costs can vary considerably between the measures of the NPHS. They 
can cover the amount of voluntary work performed and the amount of time spent 
by the end addresses to participate in a measure. Further, transportation costs are 
to consider, too. 
Intangible costs of prevention interventions stand for any sufferings or utility losses 
attributable to the NPHS among the end addressees of an intervention. This type 
of costs is neglected in the literature (see section 4). 
Output: The output comprises all activities of the FOPH that are related to the NPHS. We 
can differentiate between three types of activities: activities directly targeting the 
end addresses (e.g. LOVE LIFE campaign targeting the general population, the 
production of a brochure targeting men having sex with men), activities aiming to 
influence the partner institutions (e.g. contracts with partners for the provision of 
prevention services) and activities aiming to enhance the structural conditions (e.g. 
elaboration of guidelines, production and promotion of policy relevant evidence). 
The scope of action of the FOPH is shaped by the Swiss political system (e.g. 
competencies of the three federal levels). 
Outcome: We can differentiate between three types of outcomes understood as intermediary 
effects of the NPHS 2011-2017.  
Change of behaviour of the end addressees: The causal relation between the in-
terventions and behavioural change (intended reduction of sexual risk behaviour) 
is thought to work through mediators derived from behavioural science theories. 
Such mediators drive behaviour changes and include increase of knowledge, 
changing cognitions (e.g. increase positive attitudes and beliefs about risk reduc-
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tion), addressing emotional states (e.g. decrease of negative moods, increase self-
esteem, group pride), influencing social norms and support, providing training (skill 
building) and facilitating the use of relevant services and supplies (Herbst et al. 
2007: 41). Sexual behaviour outcomes include, for example, an effective risk re-
duction strategy, a decrease of the number/proportion of unprotected sex acts, in-
crease of condom use during sex acts. Testing behaviour outcomes are relevant 
too. 
Change of behaviour of the partners/ multipliers: The NPHS aims for the partners 
to increase or maintain their contributions to HIV/STI prevention in Switzerland. 
Partners should act in accordance with the NPHS and direct their efforts to the 
(particularly affected) end addressees or to structural conditions that support and 
empower the end addressees to maintain or improve their sexual health. Key part-
ners are the cantons, educational institutions, non-governmental organisations 
such as the Swiss Aids Federations and its members, Sexual Health Switzerland 
and its members, regional and local HIV/STI centres, medical associations as well 
as medical HIV/STI specialists (FOPH 2010:129-132). 
Change in the structural conditions: The NPHS aims to improve structural condi-
tions to support and empower the Swiss inhabitants to exercise their sexual rights 
and maintain or improve their sexual health. Conditions are such "that people can 
fully live undisturbed, low-risk sexuality in a self-determined manner and with mu-
tual respect" (FOPH 2010: 9). Concrete improvements include for instance the in-
tegration of age-appropriate sexual health education into the curricula of obligatory 
and post-obligatory schools or the empowerment of the gay community. 
Impact: The intended impact encompasses a decrease of HIV/STI infections, a reduction 
of unwanted pregnancies as well as an improvement of the sexual health of the 
Swiss population. (FOPH 2010: 77-78). This impact should ultimately lead to an 
increase of the quality of life in terms of health and life expectancy. 
Benefit: The benefit of the NPHS 2011-2017 calculates the monetary value of its conse-
quences. We can differentiate between the direct benefits (e.g. savings of treat-
ment costs due to less HIV/STI infections), the indirect benefits (e.g. productivity 
gains due to improved health statuses of the (target) population) and the intangible 
benefits (e.g. health status maintenance or improvement). A societal perspective 
includes all type of benefits that can occur at the outcome or impact stages. 
This chain of effects highlights that causal chains between the input and the outcome respec-
tively the impact are of different length and complexity. These differences in complexity 
should be acknowledged when prevention measures are compared (e.g. prevention meas-
ures directly targeting the behaviour of the end addresses vs. prevention measures that aims 
to enhance structural conditions). As the NPHS is implemented in a multilevel setting (three 
state levels and multiple actors) it is important to realize that a cost-effectiveness-analysis 
(CEA) could not only investigate the relation between input and the effects among the end 
addresses (outcome) or at the level of society (impact) but it could be of interest to analyse 
the relation between input and the outcome among the partners of the FOHP. This latter type 
of analysis concentrates on the relation between the costs and the activities of the partners. 
In other words, such an analysis investigates the resource flow in a multilevel setting. It could 
reveal how much resources are actually allocated to the activities on the three axes of inter-
vention at the cantonal level. 
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4 Overview of the state of the art in the field of economic evalua-
tion of HIV/STI prevention 
This section aims at giving an overview of the state of the art in the field of economic evalua-
tion of HIV/STI prevention. To do so, we looked into the literature regarding Switzerland as 
well as the current practises of international organisations and, furthermore, conducted a lit-
erature analysis of scientific studies and reviews. 
4.1  Swiss literature 
There is no economic evaluation of HIV/STI prevention measures for Switzerland available. 
However, there are a few studies that provide economic information for this public health 
area (e.g. assessment of the social costs of HIV, Zurn et al. 2001). Further, economic analy-
ses dealing with other fields of prevention and health promotion are of relevance for reasons 
of comparisons as well as for methodological experiences. We have searched the relevant 
Swiss data bases (ARAMIS, FORS Research Inventory) as well as the websites of relevant 
organisations for economic analyses dealing with prevention and health promotion interven-
tions in Switzerland. 
4.1.1  Economic information in the field of HIV/STI prevention in Switzerland 
The study by Zurn et al. (2001) is the most comprehensive economic information currently 
available in the field of HIV. It assessed the social cost of HIV for the reference year 1998. 
The authors performed a "bottom-up" analysis and estimated various components of the so-
cial cost including direct (outpatient and inpatient care costs) and indirect costs (morbidity 
and mortality costs). The study results showed that annual cost per patient in Switzerland for 
the year 1998 is CHF 21'000 and CHF 14'400 for direct and indirect costs respectively (ibid. 
54). The total HIV social cost, including direct and indirect costs, amounted to CHF 443 mil-
lion in Switzerland for the year 1998. The study also estimated the costs for HIV/STI preven-
tion at the nationwide level for the year 1998. The estimate for HIV prevention costs ranges 
from CHF 41 to 62 million (ibid: 53). The assessment of the prevention costs concentrated on 
the main programmes related to HIV as "an exhaustive review and cost assessment of all 
prevention activities directly or indirectly associated with HIV would be extremely difficult" 
(ibid: 20). The assessment included cost measurements for primary prevention and secon-
dary prevention, namely screening and post-exposure prophylactic treatment (PEP). For the 
former, cost measurement comprised the HIV prevention budget of the FOPH in 1998, an ex-
trapolation of data from the canton of Vaud for the cantonal and communal HIV prevention 
costs, condom sales as well as the cost of syringe exchange programmes. Voluntary work 
was also considered based on data of the Swiss AIDS Federation and valued using the 
"market cost approach". This study also estimated the cost-effectiveness of HIV prevention 
per averted cases. However, the analysis was not based on data about the effectiveness of 
the HIV prevention measures. In contrast, the authors performed a scenario analysis based 
on the decline of newly reported HIV infections between 1991 and 1998 (decrease of 1'487 
cases). They assumed that the reduction in the number of HIV infection cases is attributable 
to prevention and performed a scenario analysis varying the prevention effect between 10 to 
90 per cent of the reduction (ibid 54). The authors concluded that HIV prevention is a cost-
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effective intervention, under the hypotheses that life expectancy of a patient under treatment 
is longer than ten years. 
More recently, Auerbach and Früh (2012, confidential report) performed a rough estimation 
of the direct medical costs for an HIV patient in ART based on data obtained from medical 
service provider of Zurich and St. Gallen. Thus, this estimation provides new data on the 
costs of outpatient care (treatment, laboratory, drugs). 
Further studies (Neuenschwander et al. 2005a, b; Rosenbrock et al. 2012: 29, 40; Almedal 
2012: 14; Plüss et al. 2009: 68-78) collected and analysed the developments in HIV preven-
tion budgets of selected aids help organizations. These studies did not analyse the cost-
effectiveness relation of HIV prevention but concentrated on the development of resource al-
location.  
4.1.2  Experiences from other prevention and health promotion studies in Switzerland 
In the last fifteen years, there has been an increasing interest in cost analysis and economic 
evaluation in the fields of prevention and health promotion in Switzerland (e.g. Brügger et al. 
2004; Gutzwiller/Steffen 2000; Iten et al. 2009; Jeanrenaud et al. 2005; Mauch/Balthasar 
2007; Telser et al. 2010; Schneider et al. 2009; Wieser et al. 2010).4
Some of these studies concentrated on the analysis of the literature (Brügger et al. 2004; 
Meier 2004; Schmidhauser et al. 2009), others aimed to transfer the results about the cost-
effectiveness of prevention interventions from other countries to Switzerland (Iten et al. 2009, 
Galani 2007). A third group of studies measured the costs of a selected health problem 
(Jeanrenaud et al. 2005, 2003, Telser et al. 2010) or performed an economic evaluation of 
particular interventions in Switzerland (e.g. Frei 2001; Fueglister-Dousse et al. 2009; Gutz-
willer/Steffen 2000; Mauch/Balthasar 2007; Wieser et al. 2010). These studies covered top-
ics such as addictions (illegal drugs, alcohol, tobacco), obesity, diabetes, stress, vaccinations 
or road accidents. 
 The FOPH commis-
sioned the majority of these studies. 
The review of these studies reveals the difficulty to obtain (comprehensive) data on the costs 
of the prevention or health promotion interventions in Switzerland. There is no centralized 
data on prevention or health promotion measures and on the allotted resources. Some stud-
ies estimated the costs based on data of the national level and on an extrapolation of the 
cost data of one canton (Jeanrenaud et al. 2005: 36). To our knowledge, Fueglister-Dousse 
et al. (2009a: 58-59, b: 13) performed the most comprehensive approach to gather data on 
cantonal expenditure for prevention. The authors surveyed civil servants responsible for 
health promotion at the cantonal level (Kantonale Beauftragte für Gesundheitsförderung) in 
order to measure the cantonal investments for the prevention of smoking and alcoholism be-
tween 1997 and 2007. This survey showed that cantonal health services do not have a com-
plete view of the operations carried out on their territory and do not know the sums invested 
in the prevention of smoking and alcoholism (Fueglister-Dousse et al. 2009a: 58). The au-
thors pointed out that it was difficult to determine the fraction of the expenditure allocated to 
tobacco or alcohol, especially when the preventative actions relate to several products. Fur-
ther, they emphasised that cantonal budgets are often not defined by substance but rather 
                                               
4  Appendix 11.1 provides an overview of the economic analyses in the fields of prevention and health promotion in Switzer-
land. 
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globally dedicated to prevention and health promotion. Additionally, they stressed that the in-
vestments by nongovernmental organization were often unknown. Thus, the authors con-
cluded: “The lack of centralised data for the cantonal actions constitutes a major obstacle to 
a consistent evaluation of the return on the investments for the prevention.” (Fueglister-
Dousse et al. 2009b: 13). 
The conceptualisation and measurement of the effectiveness of the interventions vary across 
the studies. Only few studies are based on effectiveness data obtained by an evaluation of 
(behavioural) effects of the respective interventions implemented in Switzerland (Telser/ 
Zweifel 2000, Gutzwiller/Steffen 2000; Frei 2001). These studies concentrate each on a par-
ticular intervention (prevention of hip fractures respectively heroin maintenance treatment) 
and performed an ex-ante and an ex-post measurement. Other studies used effectiveness 
information gathered in other countries (e.g. Galani et al. 2007; Iten et al. 2009). Alterna-
tively, the cost-benefit analyses by Wieser et al. (2010: 25) used a "multivariate regression or 
other statistical techniques" to estimate the magnitude of the intervention's effect in the field 
of smoking, alcohol and road accident prevention. 
Most of the studies differentiate between direct, indirect and intangible costs that are ex-
pended as a result of a health problem. In the case of preventive or health promotion inter-
ventions these costs are to be saved by a decrease of the respective health problem. While 
some studies concentrated on direct and indirect costs and benefits (e.g. Frei 2001; Mauch/ 
Balthasar 2007), others aimed to cover the intangible values. Some of the these studies per-
formed a cost-utility analysis (CUA) and introduced the approaches of QALY (Galani et al. 
2007; Iten et al. 2009) or DALY (Wieser et al. 2010; Fueglister-Dousse et al. 2009a) to con-
sider savings in terms of quantity and quality of life. Cost-benefit analyses that estimated the 
intangible costs through willingness-to-pay (WTP) are scarce (Telser/ Zweifel 2000). 
We can sum up that existing studies for Switzerland demonstrate the difficulty to gather data 
on the resources spent at the subnational level by cantonal and communal authorities as well 
as by other private actors. As there are only few studies that performed an economic evalua-
tion, the possibilities for comparisons with other prevention areas are rather restricted. We 
can conclude that there is not yet a dominant practice how to conceptualise and measure the 
consequences of prevention interventions for the purpose of an economic evaluation. 
4.2  Current practice of international organizations 
This section analyses the current practices of international organisations in the field of eco-
nomic evaluation on the topic of public health. We focus on recommendations, standards and 
up-to-date tools given out by the World Health Organization (WHO), UNAIDS, World Bank, 
OECD, European Centre for Disease Prevention and Control (ECDC) and Centers for Dis-
ease Control and Prevention (CDC).  
For this purpose, we have searched these organisations’ homepages for guidelines, recom-
mendations, previous research and other literature on the topic of economic evaluations in 
the field of public health.5
                                               
5  The search was conducted primarily through embedded search engines on the organisations’ websites and subsequently 
following links. Also, external search engines were used in order to look for more specific documents (such as cost-
effectiveness analysis of HIV Prevention Interventions) which may not have been found through the primary technique. The 
search strategy can be found in the appendix (
 We identified 15 documents that deal with economic evaluation of 
11.2) 
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public health interventions6. Only two of them focus primarily on economic evaluations (UN-
AIDS 1998 and WHO 2003). Studies conducting economic evaluations are rare7
Two documents contain rather technical information: UNAIDS (1998) looks into the back-
ground, issues and challenges of cost-effectiveness analyses and outlines possible solu-
tions. The second technical document, also by UNAIDS (2009), looks into the assessment of 
national spending on AIDS, giving out definitions and classifications for relevant programmes 
and services as well as for the tracking of resources. WHO (1994) is a training manual for 
programme managers eager to conduct cost analyses. Further, WHO (2009) is a report as-
sembling advices for the health sector on the response to HIV/AIDS. It presents the crucial 
interventions the health sector should deliver and provides key references and links to re-
sources. Furthermore, World Bank (2004) contains a review of literature on priority setting in 
health care which looks at the problem of choosing the optimal mixture of programmes that 
can be afforded with a given budget, while WHO (2006) portrays proceedings from a work-
shop on scaling-up HIV services in countries and providing them with guidelines on policy 
formulation, implementation and evaluation. 
 and thus the 
organisations provide hardly any recommendations on how to undertake such studies. Most 
of the documents included in the review are guidelines or frameworks (CDC undated, OECD 
2008, UNAIDS 2000a, 2000b, 2007 and 2010, WHO 2003 and 2008.) which focus on costing 
or evaluations (often in connection with monitoring) as tools. 
We will now first look into the recommendations regarding cost analysis and afterwards into 
those regarding efficiency analysis. 
4.2.1  Findings: Cost Analysis 
The analysis of the current practices of international organisations shows that no common 
approach has yet been established in order to specify the costs associated with the imple-
mentation of a public health intervention. In the following we present the different views on 
the important aspects regarding the conceptualization of the costs, as well as on the collec-
tion and analysis of cost data. 
The question of whose costs need to be calculated is answered by the perspective taken. In 
the reviewed documents, the societal, provider, public sector and private perspectives are 
discussed. UNAIDS (2000b: 8) opted in its "Costing Guidelines for HIV Prevention Strate-
gies" for a public sector perspective, though private costs may be included if they contribute 
towards financing services. WHO (2003: 19-20, 2008: 14) on the other hand, prefers the so-
cietal perspective, arguing that all costs should be taken into account regardless of whom 
they are covered by (WHO 2003: 19). 
Assessing the level on which costs are to be collected, WHO (2003: 30) argues that because 
some types of costs (such as administrative costs) vary across settings, the analysis needs 
to be undertaken on a sub-regional, rather than a global level. UNAIDS (2000a: 5-7) men-
tions four possible levels for the evaluation of AIDS programmes: international, national, dis-
trict and project level. The literature review shows that costs can be classified in many ways 
and the organisation agrees that all relevant costs need to be included and categories must 
                                               
6  The bibliography of the included documents can be found in the appendix (11.3). 
7  Country reports with the UNAIDS are common and some do include cost-effectiveness exercises, but these centre the 
treatment. Generally, these reports focus on the country’s HIV/AIDS programmes, explaining them as well as covering fi-
nancing and costing aspects. 
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not overlap. UNAIDS (2000b: 67-69) provides useful information on types of costs: Economic 
(opportunity) costs are separated from financial costs. The latter represents actual expendi-
tures on goods and services purchased (how much money has been spent?), while the for-
mer also recognizes the cost of using resources. Which type of costs is to be included in an 
economic evaluation, depends on the objectives of the analysis. Anticipating the collection of 
cost data, though, it is recommended for cost-effectiveness studies to use the full economic 
costs of the resources consumed. WHO (2003: 35) gives an overview of possible classifica-
tions (by input category, intervention activity or organizational level), and points out that both 
programme and patient costs should be identified. WHO (2003: 41-42) also points out that 
volunteer labour should be included as costs if it cannot be assumed that this volunteer la-
bour will always be available. If included, it should be at the cost of employing others to un-
dertake the task (e.g. wage of health personnel). UNAIDS (2000b: 83) includes work of vol-
unteers in the economic costs (see above). A further distinction is made by WHO (1994: 5-9) 
and UNAIDS (2000b: 40-41) between recurrent or capital costs. Recurrent costs are regular 
expenditures such as for personnel (including volunteers), supplies or operating costs. Capi-
tal costs are expenditures for more durable items such as buildings, start-up activities or one-
time publicity campaigns. 
Regarding data collection, UNAIDS (2000b, 2009) provides hands-on forms or spread sheets 
for the in-field data collection of costs or assessments of spending that are applied on an 
regular basis in country reports8. Some documents state practical hints such as what kind of 
spending categories exist and how they are defined. For example, in its guide to a national 
spending assessment, UNAIDS (2009: 9) differentiates between three dimensions of cost 
data: financing, provision and usage of services.9
Regarding methodological issues, it is common for the cost analysis to include discounting 
and a sensitivity analysis: The collected cost data is recommended to be discounted at an 
annual rate of 3% (WHO 2003: 71) or as UNAIDS (2000b: 69-70) recommends, at the dis-
counting rate used by the relevant economic planning office or Ministry of Finance. If no such 
rate is available, then a “rate can be taken from economic project appraisals done by other 
organizations such as the World Bank.” 
  
Sensitivity analysis is also recommended: WHO (2003: 71) advices for the sensitivity of the 
results to be tested to a rate of 6%, while UNAIDS (2000b: 70) offers three options: “(i) your 
choice of rate; (ii) twice that rate; (iii) half that rate.” 
4.2.2  Findings: Efficiency analysis 
Generally, economic evaluation is seen as an essential tool to ensure that the HIV response 
is based on evidence and provides information useful for making decisions about resource 
allocation (e.g. CDC undated: 10-12, UNAIDS 2008: 2, WHO 1994: 67). 
Regarding different types of economic evaluation, it appears that efficiency analysis (as a 
generic term, thus also including CUA and CBA) is preferred, as it is mentioned, considered 
                                               
8  See http://www.unaids.org/en/dataanalysis/knowyourresponse/nasacountryreports/ [13.03.13] for such reports. 
9  Each dimension consists of two sub-dimensions: Financing consists of financing agents and sources, the former being enti-
ties that pool resources and also make programmatic decisions, the latter being entities that provide money to the agents. 
Provision of services distinguishes between providers, who are engaged in production, provision and delivery of the ser-
vices, and production factors or resource costs meaning the inputs (labour, capital etc.). Usage includes HIV-related inter-
ventions and activities as well as beneficiary segments of the population (e.g. MSM). 
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or recommended in several documents (OECD 2008 55; UNAIDS 1998: 3, 2000b: 44-45 and 
2010: 37; WHO 1994: 55-73, 2003: 3-5, 2006: 7 and 2008: 5-7, 10; World Bank 2004: 7-12). 
OECD (2008: 55) points out CBA as “the most established approach for the evaluation of in-
tersectoral programmes.” Further, OECD recommends combining CBA with CEA in order to 
make the assessment relevant to different decision and budget perspectives. This is also 
seen as an improvement regarding the comparability of results across interventions. 
Perspective-wise, OECD (2008: 47) sees the perspective of the decision maker as prevalent, 
but WHO (2003:19-20) prefers the societal perspective. UNAIDS (1998: 4, 2000b: 8) points 
out that the perspective taken depends on the objectives of the study, but takes on the pro-
viders' perspective in UNAIDS (2000b: 8). 
With regard to consequence measures, different approaches are known and discussed. 
Standardization of measurement, which involves clear case definitions and the use of com-
mon consequence measures, is widely suggested. For example, strengths and weaknesses 
of consequence measures such as DALY gained, infections averted, numbers educated or 
counselled and more, are briefly discussed in the UNAIDS’ (2000b: 43) Costing Guidelines 
for HIV Prevention Strategies. The World Bank (2004: 9-10) looks into the most common 
ways of measurement as well: for each of the consequence measure, strengths and weak-
nesses (problems) are identified, however, only few recommendations regarding the decision 
on which measurement of consequences to use are made.10
Research designs for the measurement of consequences are only marginally discussed. Ac-
cording to UNAIDS (2000b: 43), the outcomes should be measured in randomized, controlled 
trial (RCT). Likewise, CDC (undated: 10) names RCT “the evaluation design that is consid-
ered to produce the strongest evidence”. CDC acknowledges the expensiveness, time-
consuming and some ethically debatable aspects of RCT and thus names quasi-
experimental designs as an alternative. UNAIDS (2007: 52) considers surveys as important, 
because they help assessing “the perceptions, behaviours, knowledge, attitudes and infec-
tion status of most-at-risk populations targeted by an HIV prevention project or intervention.” 
 OECD (2008: 55) sees quality-
adjusted life years (QALY), disability-adjusted life years (DALY) and healthy life years (HLY) 
as appropriate consequence measures, while (secondary) infections averted is also regarded 
as a primary consequence (UNAIDS 2000b: 42-44). World Bank (2004: 9) sees QALY as the 
most prominent measure, but the WHO (2003: 65) prefers DALY. Other consequences de-
scribed include improved knowledge, changed attitudes, behaviour change and more. Such 
outcomes are understood as eventually having an impact on HIV or STI transmission (UN-
AIDS 2000a: 15). 
Interventions should be measured against the ‘null’, “i.e. the situation that would exist if none 
of the set of interacting interventions were implemented” (WHO 2003: 27).  
Measuring secondary infections requires knowledge of the epidemiology, behaviour patterns 
and transmission efficacy (see especially UNAIDS 1998: 7-8). It is also highlighted that, al-
though it is possible to calculate the number of HIV infections directly prevented, measuring 
secondary infections requires model-based evaluation or randomized clinical trials (UNAIDS 
2000b: 42-43).  
                                               
10  An overview of the discussed strengths and weaknesses of consequence measures can be found in the appendix (11.4) 
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The World Bank (2004: 7) emphasizes in "The Economics of Priority Setting for Health Care" 
the importance of including wider societal benefits of an intervention in CBA. These are 
benefits to third parties like relatives (reduction in time spent caring for the patient), the wider 
community (reduction in infection risk), or the economy in general (effects on the labour mar-
ket). 
The consensus is that “the calculation of the final impact can be quite difficult and depends 
on the nature of the prevention strategies being considered” (UNAIDS 2000b: 44). 
Methodologically, both quantitative and qualitative methods are to be considered: Quantita-
tive methods are essential for identifying the extent to which programme objectives were 
achieved whereas qualitative methods are important for gaining a more complete picture of 
risk behaviour or factors affecting the success of an intervention and for interpreting the 
quantitative data (UNAIDS 2007: 51-52).  
Discounting is advised for consequence measures as well, because it is needed to reflect 
uncertainty and time preferences (World Bank 2004: 8-9). WHO (2003: 54) advices to dis-
count “future healthy years gained by an intervention at a 3% rate to their present values 
[…].” Sensitivity analysis is also recommended but seen as more relevant for variables that 
cannot be measured and for which there is no probability distribution: “For CEA, this applies 
to the two key social choice variables - the discount rate and age weights” (WHO 2003: 74). 
For variables which can be measured and for which there is an underlying probability distri-
bution, probabilistic uncertainty analysis is suggested to explore the impact of variability. 
4.2.3  Summary 
This chapter reviewed the international organisations’ literature on cost analysis and eco-
nomic evaluation. The main conclusion is that although the organisations deal with this sub-
ject, recommendations are given out with reservations. The subject and aim of the studies is 
mentioned in this context, because it influences the choice of methods and the scope of 
analysis. 
The literature on cost analysis has shown that the organisations agree on the necessity to 
classify and distinguish types of costs, but not on a specific way to do so. Discounting and 
sensitivity analysis is regarded as a standard procedure while most other recommendations 
differ. 
Regarding economic evaluations, the international organisations’ documents, in summary, 
brought forward a consensus: such analyses are widely known and supported by all the or-
ganisations under scrutiny here. While some recommendations are made, they mostly re-
main at a simple level. Again, discounting and sensitivity analysis are advised. The main dif-
ficulty is thought to lie in the calculation of the final impact of an intervention. 
4.3  Overview: Economic evaluations in the field of HIV/STI from 1996 to 2012 
This chapter reviews the scientific publications on economic evaluations in the field of 
HIV/STI, published in peer-reviewed journals between January 1996 and September 2012. It 
is based on a systematic search of various publication databases.11
                                               
11  The following english databases were searched: NHS EED National Institute for Health Research (Economic Evaluation 
Database), Web of Science, ERIC (education resources information center), Campbell library and Cochrane library. The 
 Overall, 108 publications 
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were found12, of which 92 were original economic evaluations of HIV/STI prevention meas-
ures, and 16 were reviews on the topic. In the following, we give an overview for all of these 
108 documents. Thereafter, we present a more detailed analysis on a selection of the most 
relevant articles (section 4.4).13 Figure 3  shows the sustained research interest for economic 
evaluations of HIV/STI prevention.  
Figure 3: Studies and reviews by the year of their publication 
 
First authors from the USA (70.1% of all studies/reviews) and the UK (10.3%) clearly domi-
nate. Geographically, the publications concentrate on the efficiency of prevention interven-
tions in western countries and in particular in the USA. While this finding reflects the state of 
the research in this field, it can partly be explained by the bias introduced by using only Eng-
lish search terms and databases.  
Table 4 displays the infections and regions covered by the studies and reviews. HIV has at-
tracted more research interest than other STIs: 70 studies and 14 reviews concentrate on 
HIV, 12 studies deal with HIV and STI while 10 studies and 1 review focus on STI other than 
HIV.  
Table 4: Infections and regions covered by the literature on economic evaluations of HIV/STI prevention 
 HIV HIV/STI STI Total 
Africa 10 (1) 4 (-) - (-) 14 (1) 
Asia 5 (1) 1 (-) 1 (-) 7 (1) 
Latin America 1 (-) 1 (-) - (-) 2 (-) 
Eastern Europe 2 (-) - (-) 1 (-) 3 (-) 
Western Countries (AUS, NZ, USA, CAN, West. Europe) 49 (5) 6 (1) 8 (-) 63 (6) 
International 3 (7) - (-) - (1) 3 (8) 
Total number of studies / infections 70 (14) 12 (1) 10 (1) 92 (16) 
Cells contain: Absolute number of economic evaluation before (number of reviews in brackets). 
 
                                                                                                                                                  
search procedure and the applied English search terms are described in the appendix (11.2). The considered databases 
comprise journals (documents) in other languages than English that would be found with English search terms too. Addi-
tionally, we searched the relevant German and French journals as well as central public health organisations of France and 
Germany. Further, we performed rough search with French and German search terms in a database that allow searches in 
these languages (scorpus). These search activities did, however, not produce conclusive results. 
12  The bibliography for the included 108 documents can be found in the appendix (11.5) 
13  The Codebook for the literature analysis can be found in the appendix (11.6) 
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Table 5 shows the target populations covered by the economic evaluations and the reviews. 
An economic evaluation can deal with several target populations. Such cases were coded 
multiple. The economic evaluations and reviews predominantly deal with the first axis, the 
second is also represented well, but axis 3 is only covered by eight studies and two reviews. 
The analysed period (1996 through 2012) shows no steady development of the number of 
studies conducted per axis. In 2005, there seems to be a change of trend as the number of 
studies on the general population (axis 1) has more than doubled.14
Regarding the interventions considered, there is a difference between studies conducted for 
western countries and those for other regions such as Africa. In studies concerned with 
western countries, behavioural interventions such as counselling and education are - screen-
ing and testing set aside – predominant, while studies on Africa mostly focus on male cir-
cumcision, condom distribution or availability programs and voluntary testing and counsel-
ling. 
 The reason for this is an 
increase in studies concerned with voluntary counselling and testing (until 2004: 4, after-
wards: 13), screening (until 2004: 13, afterwards: 19), male circumcision (until 2004: 1, af-
terwards: 7) and also mass media (until 2004: 3, afterwards: 9). Further, there is a slight in-
crease in studies covering most of the other interventions. Overall, 62 publications included 
the target groups assigned to axis 1, 26 included such of axis 2 (high risk of exposure) and 
nine such of axis 3 (infected people and their partners). 
About 60% of the studies were conducted retrospectively, while prospective studies account 
for about 40%. Within axes 1 and 3 the number of retrospective and prospective studies is 
near-balance, but for axis 2 retrospective studies represent two thirds. 
The studies mostly analysed one intervention, either comparing it to the case where the in-
tervention doesn’t exist (on/off comparison) or to other variations of the intervention (e.g. dif-
ferent extents). These two types of comparison account for a bit more than two thirds of all 
studies. Other bases of comparison include comparing different interventions’ effectiveness 
with each other or with respect to treatment. Taken together, these make up for approxi-
mately a fourth of all studies. 
For both the time perspective and the basis of comparison, no clear time trend can be identi-
fied as their use is scattered over the analysed time period. This result also holds true for 
these variables’ relation with the analysed target groups and interventions. 
The studies mostly used QALY and/or infections prevented to measure the effects of the in-
terventions, independently from the axis considered.  
                                               
14  For axis 1, from 1996 to 2004 20 studies have been included, while for 2005 to 2012, 42 studies have been found. 
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Table 5: Target populations covered by the economic evaluations (and reviews) of HIV/STI prevention 
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Africa 8 (-)  4 (-) 1 (-) 1 (1)  3 (1)     1 (-) 
Asia 4 (1)    1 (1) 2(1) 5 (1) 2 (-) - (1) 2 (1)  1 (-) 
Latin America 1 (-)    1 (-) 1(-) 2 (-)      
Eastern Europe 2 (-)        1 (-)   1 (-) 
Western 
Countries  
AUS, NZ, USA, 
CAN 
9 (1) 7 (1) 2 (-) 2 (2) - (1) 15 
(3) 
1 (-)  14 
(3) 
3 (1) 3 (1) 5 (1) 
Western Europeb 1 (1) 2 (-) - (1) - (1)  1(-)   2 (-) 0 (1) 1(-)  
International  
No western 
countries in-
cluded  
2 (2)  - (1)  1 (2) 1(-) 1 (2)  - (2)    
Including 
western coun-
tries 
- (3)  - (1) - (1) - (2) - (3)   -(3)    
Total number of studies / 
target groups 
26 
(12) 
15 
(2) 
6 
(3) 
3 
(4) 
4 
(7) 
20 
(7) 
12 
(4) 
2 
(0) 
17 
(9) 
5 
(3) 
4 
(1) 
8 
(2) 
N = 108 studies 
Cells contain: Absolute number of economic evaluation before (number of reviews in brackets). 
Studies/reviews dealing with several target populations are counted multiple (for each target population they are dealing with). 
Hatched cells depict areas not covered by the analysed literature 
a including studies/reviews that deal with HIV screening but also (an)other intervention(s). 
b Barham et al. (2007) includes both Western European countries as well as AUS, CAN, USA; this review was assigned to this 
row only. 
MSM men having sex with men, IDU injecting drug users, FWS female sex workers, MSW male sex workers. 
 
4.4  In-depth analysis of selected economic evaluations 
We selected 28 economic evaluations for an in-depth analysis, additionally collecting details 
such as the main questions of the studies or limitations of different aspects.15 On the one 
hand, this selection aimed at concentrating on economic evaluations that deal with preven-
tion interventions in western countries (i.e. Australia, New Zealand, North America and 
Western Europe). These countries are confronted with similar trends in HIV/STI epidemics. 
On the other hand, the selection aimed at covering the three axes of intervention of the 
NPHS. We included ten economic evaluations that deal with interventions targeting the gen-
eral population and selected the five most recent publications on HIV screening within the in-
tervention axis 1.16
                                               
15  A list of these articles (by axes) can be found in the appendix (
 We included all 16 economic evaluations of prevention intervention tar-
geting MSM within intervention axis 2 and all the articles on prevention interventions of west-
11.7) 
16  The older publications are less relevant with respect to Swiss HIV policy as HIV screening is not part of the current policy. 
Furthermore, the achievements in the developments of the highly active antiretroviral therapy change the prerequisites for 
screening strategies and thus, the focus on most recent publications seems to be appropriate. 
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ern countries dealing with infected people and their partners (axis 3). Some of the articles 
deal with several target groups. Seven studies dealt with more than one axis: Cohen et al. 
(2004 and 2005) dealt with all three axes, four other articles with axis 1 and 2 (Long et al. 
2010; Prabhu et al. 2011; Sanders et al. 2005; Yazdanpanah et al. 2010) and one (Varghese 
et al. 1999) with axis 1 and 3. Of all the 28 studies, 21 dealt with HIV only, the others dealt 
with either STI in general or both. Authors' affiliations correlated completely with the countries 
under scrutiny and were dominated by US-American studies: only three studies were con-
ducted elsewhere, namely Australia (Anderson et al. 2009), Ireland (Gillespie et al. 2012), 
France (Yazdanpanah et al. 2010).  
4.4.1  Topics investigated  
Table 6 shows the interventions, time perspectives, bases of comparison and types of eco-
nomic evaluation found in the studies selected for the detailed analysis. Interventions con-
cerned with screening and/or testing were dominant in studies dealing with axis 1 only. Two 
out of nine studies dealt with another intervention, while one study (Chesson 2006, dealing 
with gonorrhoea only) analysed a whole program without describing the interventions, but 
categorizing them as structural and individual interventions and also looking into treatment. 
Regarding studies concerned with axis 2 or 3 only, it seems that interventions dealing with 
counselling or educational approaches are most common. In axis 2 some other interventions 
appear as well, but only screening is looked at in more than one study. No other interven-
tions were analysed for axis 3. It stands out, though, that studies dealing with more than one 
axis analysed more and a greater variety of interventions. For example, partner notification, 
appears three times while mass media campaigns, voluntary counselling and testing (VCT) 
and others are also of interest. Overall, and apart from screening and/or testing, interventions 
with a counselling or educational focus are found most frequently. Moreover, the studies 
concerned with more than one axis are found to have more general goals in terms of the use 
of cost-effectiveness data. For example, Cohen et al. (2005) aim at optimizing the use of 
government funds while Yazdanpanah et al. (2010) perform a setting-specific analysis of HIV 
screening strategies for France. Analyses are mostly conducted retrospectively, but prospec-
tive studies make up a substantial part as well. Within axis 1, they almost keep the balance 
whereas in axis 2, retrospective studies occur seven times, while prospective studies are 
only conducted three times. It noticeable, that these three prospective studies were con-
ducted since 2009, while the seven retrospective analyses took place in 2002 or earlier. 
Regarding the bases of comparison, we can report mixed results: In axis 1 both analyses of 
interventions against the situation in which the intervention didn’t exist (on/off, often the 
status quo is such a situation) and analyses of one intervention in different variations are 
common. In axis 2, on the other hand, on/off comparisons are most common as seven out of 
nine articles belong to this category. Not surprisingly, studies concerned with more than one 
axis were found to use other bases of comparisons more often. Three articles compare sev-
eral types of interventions and two studies looked into interventions and treatment. 
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Table 6: Interventions, time perspectives and bases of comparison of the selected economic evaluations 
 Axes (>1) 
Axis 
1 
Axis 
2 
Axis 
3 
Total 
Intervention 
 
   
 
Counselling, education 3 1 3 2 9 
Partner notification 3 0 0 0 3 
Male circumcision 1 0 1 0 2 
Voluntary Counselling and Testing 2 0 0 0 2 
Street outreach 1 0 0 0 1 
Community-based (e.g. outreach, mobilization) 2 0 1 0 3 
Condom distribution/availability 2 1 1 0 4 
Needle and/or syringe exchange/programs 2 0 0 0 2 
Mass media campaigns 2 0 0 0 2 
School based interventions 1 1 0 0 2 
Screening and/or testing 6 5 2 0 13 
Peer counselling 1 0 1 0 2 
Treatment of HIV 2 0 1 0 3 
STI treatment 1 0 1 0 2 
Overall program (no specification) 0 1 0 0 1 
Time perspective      
Retrospective 4 5 7 2 18 
Prospective 3 4 3 0 10 
Basis of comparison      
On / off 1 5 7 1 14 
One type in diff. variations 1 4 2 1 8 
More than one type 3 0 0 0 3 
Prevention interventions and treatment 2 0 1 0 3 
Types of economic evaluation      
CEA 2 5 2 1 10 
CUA 5 4 8 1 18 
n = 28. Cells contain absolute numbers.  
 
The publications do not always specify the study period explicitly. For prospective studies, 
this can be a time frame to which a model is applied. This time frame/horizon varies from one 
year to twenty-five years. Retrospective studies sometimes relate to a certain time-restricted 
intervention and name an exact time period. These retrospective studies differ regarding the 
time analysed as both longer time frames such as more than thirty years in Holtgrave (2002) 
and short time frames such as one year in Pinkerton et al. (1998) occur. 
4.4.2  Perspective and type of economic evaluation  
Analysing the perspective taken by the researchers we found that the societal perspective is 
predominant, as around half of the studies were conducted from this point of view (including 
three with mixed perspectives). The provider perspective was used in a little less than a fifth 
of the studies, while the same amount of studies mentioned none of these perspectives at all. 
Regarding the types of economic evaluation, CUA dominate, making up for almost two thirds 
of all studies, while the remaining studies are CEA. Distribution over axes shows that in axis 
1 both types are common, while for axis 2 and those studies dealing with more than one axis 
mostly CUA were performed (8 out of 10 and 5 out of 7 respectively). Interestingly, CUA 
were performed more regularly in recent years with nine of the sixteen studies dating from 
2010 or later. CEA are scattered over the years, 60% occurring between 1997 and 2002. 
Looking at axis specific development, it can be said there was a change of trend for studies 
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concerned with axis 1: CUA first appear among these studies in 2011, while only CEA were 
conducted earlier, the latest one dating from 2006. This is in contrast to axis 2 where CUA 
appear throughout the years of publication. Regarding the studies concerned with more than 
one axis, CUA appear as of 2004. 
4.4.3  Conceptualization and measurements of the costs 
Only three studies refer to overall costs only, while most of the other studies further catego-
rized costs: Personnel costs (16 studies), material costs (19 studies) and overhead costs (11 
studies) were mentioned and sometimes detailed values given. Costs that occurred for par-
ticipants and volunteers were seldom accounted for: Only seven studies (for example Lee et 
al. 2005: 113; Tao et al. 1998: 86-87; Pinkerton et al. 1997: 349-350) included participant 
costs, while costs for volunteers were included in Kahn et al. (2001: 485-486) who accounted 
for travel costs of volunteers and Cohen et al. (2004_ 1406) only. Regarding participant 
costs, travel costs as well as monetary incentives were the most common additional differen-
tiations. 
Regarding data collection, it seems that both primary and secondary data (and a combination 
of these two) were used to attain cost data of the analysed intervention. But, secondary data 
was used twice as often. While there is no striking difference between the studies concerned 
with one axis only, we found that of the studies concerned with more than one axis, only 
Cohen et al. (2004) and Prabhu et al. (2011) used primary data and used it only in connec-
tion with secondary data. The other five studies dealt with secondary data only. 
Primary data was often obtained through the staff or records of the intervention. Some stud-
ies estimated costs based on the figures available. Cooperation in obtaining data with local 
authorities can be found as well as data collection at the time of the intervention. Secondary 
data was obtained from difference sources. The use of existing scientific data was very 
common. In some cases, researchers would use it to make estimations or use it as made 
available. Data provided by government authorities was used as well. Some studies com-
bined primary and secondary data, often using certain data from published literature and 
adding intervention specific data to assess costs. 
Discounting was left out in seven retrospective and in four prospective studies equalling a to-
tal of more than a third of the studies. Those who did use discounting, mostly chose a dis-
count rate of 3%, which was then often varied in the performed sensitivity analysis (see be-
low). 
4.4.4  Conceptualization and measurements of the consequences 
The studies applied only few different consequences, with ‘quality-adjusted life years’ (QALY) 
and ‘infections prevented’ (here also including secondary infections averted and referring to 
both HIV and STI cases. Though, mostly HIV infections are meant) being the most common. 
Other measurements of consequences such as ‘life years gained’ or ‘decrease in risk behav-
iour’ are hardly ever considered. Sexual health neither seemed to be of interest. Further-
more, both studies concerned with axis 3 only used ‘infections prevented’. This may be ex-
plained through the considered intervention, as in axis 3 the goal is often to eliminate the risk 
of partners of HIV positive people to become infected.  
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Regarding data collected for the measurement of consequences, most of the studies (16) re-
lied on secondary data. These studies collected their data mostly from published studies, but 
sometimes official sources such as the Centers for Disease Control and Prevention (CDC) 
were also used. Regarding the published literature used, the various studies by David Holt-
grave and Steven Pinkerton (e.g. Holtgrave et al. 1998; Holtgrave 2002; Pinkerton et al. 
1997, 1998, 2000b, c, 2001b, 2002a, b; Pinkerton/Holtgrave 2000a) stand out as sources of 
parameters or values. Four studies worked with primary data only and eight studies – four 
each of axis 1 and 2 - combined primary and secondary data. It stands out that the studies 
concerned with axis 3 only are among those working with primary data only. Except for 
Varghese et al. (1999), all the studies dealing with more than one axis used secondary data. 
Furthermore, there seems to be no pattern over time at hand. 
The consequences were looked into for different time periods. They varied between one year 
which for example could be the year in which the intervention took place and some of the fol-
lowing months and ‘a life time’. The studies of axis 3 dealt with short term consequences and 
studies of axis 2 can marginally be seen as rather looking at long term results. For all others, 
no tendency is observable. 
Consequences were mostly modelled, with nine studies, including those two dealing with 
axis 3 only, using dynamic modelling. Gillespie et al. (2012), for instance, used it for project-
ing the impact of screening on prevalence. The studies working with primary data only all 
used it for modelling. Estimations are also very common: Anderson et al. (2009), for exam-
ple, estimated incidence rates. Only two studies (Pinkerton, 2000a; Prabhu et al. 2011) were 
found to have not estimated any further values. Furthermore, discounting was performed of-
ten, mostly at a rate of 3%. 
4.4.5  Sensitivity analyses 
As almost all studies conducted sensitivity analyses, this can be seen as a standard. Both 
one- and multi-way sensitivity analyses have been conducted. The authors vary both pa-
rameters of costs and of consequences, often applying different ranges. Regarding the 
ranges used, no general tendency struck the eye and they were often varied differently be-
tween parameters. Exemplarily, Long et al. (2010: 784) varied the reduction of sexual en-
counters after a counselling intervention and Sanders et al. (2005) increased baseline values 
of HIV incidence by twice and three times that value. Discount rates were also subject to 
sensitivity analyses with the common rate of 3% often varied from 0% - 5%. 
4.4.6  Limitations 
Almost all studies discuss limitations of their analyses. Regarding the cost side, limitations to 
retrospective collection of data were mentioned more than once, as posing an extra chal-
lenge and potentially leading to imprecise values. Some authors also criticised that because 
they ignored certain types of cost, such as start-up costs or fixed costs, the overall amount 
may have been underestimated. 
Limitations regarding the measurement of consequences were discussed more extensively 
but are also very diverse. The fact that data was estimated or modelled rather than directly 
measured is criticised several times. For example, Marseille et al. (2011: 93) is critical of his 
estimates of intervention effects because they are based on changes in behaviour reported 
by participants. Similarly, Pinkerton et al. (1997: 354 and 1998: 1241) relied on self-reported 
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sexual behaviour data while Holtgrave et al. (2012: 1119) reckons measuring the impact of 
an intervention on HIV incidence would be ideal, but is too expensive to conduct. Limited 
data availability was mentioned by several studies. Furthermore, the strength of evidence re-
garding the effectiveness of an intervention was questioned. The extrapolation of assump-
tions from one context to another was also discussed as a possible bias in the estimation of 
consequences: Gillespie et al. (2012: 226) used data from the United Kingdom and applied it 
to Ireland, which they criticises as a limitation of their study. 
General limitations are discussed as well. It is often said that some model assumptions can 
be questioned as they may overestimate cost-effectiveness. For example, Heumann et al. 
(2001: 642) criticised their assumption that people who do not receive a referral (e.g. to HIV 
testing) in the context of the intervention, do not seek prevention services on their own. If 
they do, the consequences of the intervention may apply even though no costs have been 
spent in that case. This leads to an over-estimation of the intervention’s cost-effectiveness. 
Furthermore, researchers acknowledged that their models simplify reality, e.g. sometimes 
leaving out important aspects such as secondary infections. Furthermore, some studies 
pointed out small sample sizes as possible sources of biases.  
4.4.7 Summary 
To sum up, we can say that the majority of the studies examined one intervention only, either 
in an on/off (intervention takes place or not) situation or by considering variations of the inter-
vention. Researchers predominantly adopted a societal perspective for their analyses and al-
though both CEA and CUA are common, CUA certainly overweigh and seem to be the more 
recent state of the art. Costs were often categorised into personnel, material and overhead 
costs. But participant and volunteer costs were seldom accounted for. Regarding cost data, 
researchers turned to both primary and secondary data, while for data regarding the conse-
quences, the use of secondary data overweighs. QALY and infections prevented were the 
most common measures of consequences, as sexual health was considered in no study. 
Methodologically, both discounting and sensitivity analyses were conducted, both for cost 
and consequence data. Researchers pointed out that data collection was often marred by the 
retrospective analysis and data on consequences was often relying on scarce amounts of 
data available. 
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5 Data availability 
The assessment of the available data for an economic evaluation of prevention measures in 
the field of STI/HIV concentrates on continuous and recent Swiss data sources, mainly pub-
lished after 2003.17
Table 7
 Since 2004, the FOPH concentrates on the monitoring of the risk behav-
iour of the relevant target populations and established a “second generation surveillance sys-
tem” (e.g. Frey/Kübler et al. 2011, Dubois-Arber et al. 2012). Additionally, the FOPH com-
missioned a few evaluation studies, expertise and reviews on its HIV/STI policy. 
 to Table 10 provide an overview on the available data sources that can be used for 
an economic evaluation in the field of HIV/STI prevention. In the following, we will discuss 
these data along the analytical concepts of the chain of effects (see section 3). Accordingly 
the tables 7 to 10 are organized along the levels input, outcome, impact and benefit. We omit 
the process and output levels. The process level is excluded as it is not relevant for the pre-
sent topic of an economic evaluation. As defined in section 3, the output comprises all activi-
ties of the FOPH related to the NPHS. Such information is relevant for the collection of cost 
and effectiveness data. We assume that the FOPH is able to document its activities. 
5.1  Input data 
A current estimation of the direct, indirect and intangible costs spent for HIV/STI prevention 
in Switzerland is missing. However, we assume that a rough estimation of the overall direct 
costs could be calculated rather easily; e.g. based on the expenses of the FOPH and of one 
or two cantons (similar to the estimation calculated by Zurn et al. 2001: 20-28). In contrast, a 
more reliable estimation of the direct cost and in particular a differentiation between the inter-
vention axes requires a considerable research effort and raises the complexity of apportion-
ing. Any effort of collecting data in this realm should consider that sources of funding are 
multiple and thus, it might be not sufficient to survey only the respective public administra-
tions. More reliable is an approach that includes the (most relevant) local actors that imple-
ment HIV/STI prevention measures. 
• Collection of input data on the public funds of the national, cantonal and communal 
level: While it is rather easy to collect the data on third party funding, it might be more 
difficult to obtain data on the costs spent for personnel, material, overhead and infra-
structure for HIV/STI prevention measures within the public administrations. However, 
we have the impression that the latter costs are not very important at the cantonal or 
communal level (e.g. Almedal et al. 2012: 14-15, 30, Rosenbrock et al. 2012: 65-66).  
• Collection of input data on the non-governmental organisations: While these actors 
often publish their overall accounts, they might not have such data for each interven-
tion axes or for the individual prevention measures. However, as the pilot study 
shows, it is possible to obtain such data (see section 6). 
To sum up, research efforts to collect data on the direct costs of HIV/STI prevention depend 
on the number of actors involved in the measures under investigation and on the required 
degree of comprehensiveness of the calculation. The collection of data on the indirect and 
intangible costs requires additional research efforts. While responsible local organisations 
                                               
17  Between 1987 and 2003, the FOPH had established and maintained an ongoing evaluation system that included evaluation 
of specific interventions, programme monitoring, and behavioural surveillance (e.g. Dubois-Arber et al. 2003). 
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that implement the prevention interventions might be able to provide information on the indi-
rect costs (e.g. volunteer's hours, see section 6; hours per participants spent in a prevention 
intervention), the estimation of intangible costs might require a survey among the partici-
pants. However, this latter type of costs is usually omitted in economic evaluations of 
HIV/STI prevention. 
Any assessment of the economic costs of HIV/STI prevention should be based on an elabo-
rate cost data collection and analysis protocol. Such a protocol defines the necessary cost 
information (e.g. categories) and aims to ensure good quality and comparability of HIV/STI 
prevention cost data.  
5.2  Outcome data 
There are some evaluations that provide outcome data either on the behaviour of the 
FOPH's partners or of the end addresses that could be used for an economic evaluation of 
HIV/STI prevention (see Tables 7-10). 
With respect to outcome data among the end addresses, data is available for intervention 
axes 1 and 2 but not for intervention axis 3 (infected people and their partners). The data on 
the behavioural outcome among end addresses is best among MSM and the general popula-
tion. The evaluation of "Break the Chain" (campaign targeting MSM) includes a before and 
after measurement of the testing and sexual behaviour of the target population and thus pro-
vides the opportunity to measure behaviour changes (Lociciro 2012a). The evaluation of 
LOVE LIFE campaign (mass media campaign targeting the general population) provides 
data on the awareness and knowledge related to HIV but does neither include behavioural 
outcome data nor a before and after measurement (Domenighetti et al. 2009).  
The data on the behavioural effects of the prevention measures targeting IDU (except for the 
data on syringe distribution programmes) and migrants coming from countries with a general-
ized HIV epidemic is rather incomplete. There is no data available on the behavioural out-
come of prevention measures targeting particular groups within intervention axes 1 (e.g. sex 
worker's clients, travellers) and 2 (female sex workers, prison inmates). 
There is no centralised data on the activities of the partners of the FOPH with respect to im-
plementation of the NPHS on the national, cantonal or local level. Such data can be obtained 
from the partners relatively easily; however there are many partners involved and the activi-
ties manifold. Gumy et al. (2012), Almedal et al. (2012) and Rosenbrock et al. (2012) provide 
an overview on HIV/STI prevention activities in the cantons of Geneva and Zurich.  
Further, data on the effects of the NPHS on the structural conditions is very scarce. There is 
monitoring data on condom sales and syringe distribution but there is no data available on 
the effects of the NPHS on, for instance, the prevention of HIV/STI in prisons, the integration 
of sex education in school curricula or the empowerment of the gay communities. 
Additionally to data on the effectiveness of prevention measures at the outcome stage, sur-
veillance data provides information on the risk and testing behaviour of the relevant target 
populations. This data could be used to estimate behavioural effects of prevention interven-
tions at the level of target populations. However, behavioural surveillance data for particular 
targets groups are missing too (e.g. prison inmates, migrants from countries with a general-
ized epidemic, sex workers and their clients, see Dubois-Arber et al. 2012: 6-7, Kübler et al. 
2012: 8-9). An estimation (modelling) of the effectiveness of HIV/STI prevention measures 
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based on surveillance data is confronted with several limitations as it is not known who was 
actually reached with the respective prevention measures with what effect. The identification 
of and accounting for confounding factors is crucial. Further, it might be difficult to find a 
meaningful basis of comparison as Switzerland continuously invested in HIV/STI policy. 
To sum up, the measurement of the effectiveness of HIV/STI prevention measures among 
the target populations is still challenging (Smedly/Syme 2001). It has to take into account that 
the chain of effects can be long and complex, and that it is influenced by several context fac-
tors. Additionally, the outcome might require some time to occur; hence the appropriate pe-
riod of study is unclear. 
5.3  Impact data 
The following four tables (Tables 7 to 10) show that impact data is rarely available. In other 
words, existing evaluation studies do not provide information on the number of averted 
HIV/STI infection, the increase of the awareness to the value of sexual health, the improve-
ment of sexual health or the number of prevented unwanted pregnancies. There are two ex-
ceptions: The evaluation of the LOVE LIFE campaign targeting the general population meas-
ures the awareness of the general population (Domenighetti et al. 2009) but does not provide 
information on the behaviour of the target population. The evaluation of “Break the Chain” 
might provide information on the impact, too, but the final report was not available yet 
(Lociciro et al. 2012a). 
In the literature, measurements of the biological impact (incident HIV/STI) are very rare. 
Usually, behavioural outcomes are translated into an estimate of the number of infections 
averted (e.g. Holtgrave/Kelly 1997; Holtgrave et al. 2012). Thus, available outcome data and 
surveillance data could inform an estimation of the impact of HIV/STI prevention measures 
(mathematical model). As mentioned in section 5.2, there are some gaps with respect to out-
come data and surveillance data of particular target groups.  
The calculation of the optimal mix of the prevention measures of the three intervention axes 
of the NPHS would require data on the sizes of the affected groups as well as HIV/STI preva-
lence data. Such data is largely missing in Switzerland. 
5.4  Benefit data 
Tables 7 to 10 show that data on the direct, indirect or intangible benefits of HIV/STI preven-
tion measures is not available. The calculation of direct, indirect and intangible benefits of 
HIV/STI prevention measures is not possible without information on the outcome or impact. 
Providing that such data is available, the calculation of the benefits requires further data on 
the costs of HIV/STI treatment, on morbidity and mortality as well as on the costs related to 
the suffering caused by HIV/STI. Zurn et al. (2001) provide such data for the first two compo-
nents for the reference year 1998. Quantitative data on the suffering caused by an HIV/STI 
infection is not available in Switzerland. 
An update of the study by Zurn et al. (2001, see also Auerbach and Früh 2012) is feasible as 
the relevant databases still exist and in some cases might even provide better data (see Ta-
ble 20 in the appendix 11.8). On the one hand, it could be more difficult to obtain such data 
for STI other than HIV because there is no cohort study conducted on these infections. On 
the other hand, there are still some data gaps (e.g. data for home care or psychotherapy, ab-
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senteeism, informal care). Furthermore, the problem of delimiting HIV-related health prob-
lems from other health problems needs to be considered. Recent costs studies performed in 
other countries should inform such an analysis (e.g. Mostardt 2011). 
In contrast, a measurement of the intangible benefit of HIV/STI prevention requires the col-
lection of primary data (survey) as no Swiss data is available. However, it is worth to assess 
the alternative of using QALY data from other western countries. 
Finally, these remarks are clearly informed by the dominant measurements of the effects, 
namely the number of "averted infections" or QALY. These are not the only intended effects 
of the NPHS and furthermore, not all of its prevention measures prioritise these effects. 
Thus, alternative concepts are to be considered. 
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Table 7: Data sources for an economic evaluation of HIV/STI prevention measures of intervention axis 1 
Intervention axis 1 
Target groups 
Input Outcome Impact Benefit Remarks 
General population 
 
Budget of the LOVE LIFE 
campaign, FOPH 
 
Evaluation of the LOVE LIFE 
campaign (Domenighetti et 
al. 2009).  
Domenighetti 
et al. 2009 
 Budget data: Working hours of the FOPH and its partners are not included in 
this budget published on the website of the FOPH. 
Domenighetti et al. (2009) provide measurements of the awareness, knowledge 
and attitudes of the target population, but no data on the behavioural outcome 
or the impact, no before after measurements. 
Biological and behavioural surveillance data is available (national/regional 
level), (FOPH, FSO (health survey), IUMSP, eg. Jeannin et al. 2010). 
Areas of data gaps: 
− Comprehensive cost data. 
− Data on the outcome among the partners of the FOPH (further activities of the 
partners targeting the general population; e.g. counselling and testing). 
− Outcome/impact among the target population. 
Migrants from coun-
tries without a gen-
eralised HIV epi-
demic 
    Biological and behavioural surveillance data available (FOPH, FSO (health sur-
vey), IUMSP, eg. Jeannin et al. 2010). 
Areas of data gaps: 
− Cost data. 
− Outcome/impact data 
Sex workers clients  Evaluation of “Don Juan” Sex 
Worker’s Client (Balthasar/  
Dubois-Arber 2007). 
  Balthasar/Dubois-Arber (2007) assess the prevention materials, the implemen-
tation intensity and whether the target group was reached, no data on the be-
havioural outcome or the impact. 
Biological surveillance data (FOPH); behavioural surveillance data till 2007 
(IUMSP, eg. Jeannin et al. 2010). 
Areas of data gaps: 
− Cost data. 
− Outcome and impact data. 
Travellers     Biological surveillance data (FOPH), behavioural data till 2007 (IUMSP eg. 
Jeannin et al. 2010). 
Educations sector 
(incl. pupils, young 
people) 
 Coverage measure "access 
to sexual education" till 2007 
(Jeannin et al. 2010); causal 
relation to the NPHS? 
Cantonal evaluations of sex-
ual educations (see 
Kunz/Bürgisser 2007, 
www.amoirx.ch); causal rela-
tion to the NPHS? 
 
 
 
 Biological and behavioural surveillance data (national/regional level) (FOPH, 
FSO (health survey), IUMSP, eg. Jeannin et al. 2010, Swiss Addictions (health 
behaviour in school-aged children (HBSC) study), some cantonal surveys). 
Monitoring data on the cantonal practices (Spencer et al. 2001). 
Areas of data gaps: 
− Cost data. 
− Outcome and impact data. 
Shaded cells: No data available 
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Table 8: Data sources for an economic evaluation of HIV/STI prevention measures of intervention axis 2 
Intervention axis 2 
Target groups 
Input Outcome Impact Benefit Remarks 
Men having sex 
with Men (MSM) 
and male sex work-
ers (MSW) 
Estimation of the size 
of the target group, 
FOPH, forthcoming 
estimation by A. 
Schmidt. 
Pilot study on the 
costs of “Break 
the Chain 2012” 
 
Budget share of 
the AHS 2006- 
2010 (Plüss et al. 
2009). 
 
Evaluation of "Break the Chain 2012" (Lociciro et al. 2012a) 
Evaluation "Mission possible 2008" (Balthasar et al. 2008) 
Evaluation of the Checkpoint Zurich (Schwappach/ 
Bruggmann 2008). 
Coverage measure: Awareness of prevention activities 
(Lociciro et al. 2009). 
Data on the prevention activities of the partners in the can-
tons of Zurich and Geneva (Rosenbrock et al. 2012, 
Almedal et al. 2012). 
Structural prevention: Audits of minimal standards for HIV 
prevention in gay establishments (VEGAS/FOPH). 
Lociciro et 
al. 2012a  
 Lociciro et al. (2012a) include measures of HIV related knowledge, 
risk and testing behaviour of MSM and measurements of the activi-
ties of the partners of the FOPH.  
Biological and behavioural surveillance data (national, regional or 
cantonal level) (FOPH, Gaysurvey IUMSP e.g. Lociciro et al. 2009). 
Mathematical model was developed to explore the effects of hypo-
thetical prevention scenarios (van Sighem et al. 2012). 
Areas of data gaps: 
− Outreach work 
− Checkpoints (Voluntary counselling and testing facilities) 
− Prevention targeting MSW 
− Structural prevention measures 
Migrants from 
countries with a 
generalised epi-
demic 
Estimation of the tar-
get group: statistics 
on migration of the 
FSO 
Budget share of 
the AHS 2006- 
2010 (Plüss et al. 
2009). 
 
Evaluation of AFRIMEDIA (Hammer et al. 2006) 
Data on preventions activities of the partners (Man-
zanares/Ruggia 2011, Rosenbrock et al. 2012, Almedal et 
al. 2012; Gumy et al. 2012). 
  Hammer et al. (2006) provide no data on the risk behaviour of the 
target population, but concentrate on HIV related knowledge, the de-
mand for prevention materials, and on the coverage of the target 
population. 
Biological surveillance data is available, FOPH; behavioural surveil-
lance data is limited (Dubois-Arber et al. 2012, Frey/Kübler 2011; 
Kübler et al. 2012; Jiekak Dommange et al. 2009). 
Areas of data gaps: 
− Comprehensive cost data. 
− Outcome/impact data of further prevention projects targeting mi-
grants or of voluntary counselling and testing facilities. 
Injecting drug users 
(IDUs) 
 
Estimation of 
prevention costs 
(Zurn et al. 2001) 
Syringes availability, IUMSP (Jeannin et al. 2010). 
Evaluation of harm reduction facilities (Zobel/Dubois-Arber 
2004) 
Gumy et al. 2012 
  Biological and behavioural surveillance data (FOPH, IUMSP, e.g. 
Jeannin et al. 2010, Lociciro et al. 2012b). 
Areas of data gaps: 
− Comprehensive, more recent cost data. 
− Outcome/impact data. 
Shaded cells: No data available 
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Table 9: Data sources for an economic evaluation of HIV/STI prevention measures of intervention axis 2 (continuation) 
Intervention axis 2 
Target groups 
Input Outcome Impact Benefit Remarks 
Female sex workers 
Estimation of the sizes 
of the target group 
Bugnon et al. 2009. 
 
Budget share of 
the AHS 2006- 
2010 (Plüss et al. 
2009). 
 
Annual reports of APiS (AHS). 
Data on preventions activities of the 
partners (Bugnon et al. 2009, Rosen-
brock et al. 2012, Almedal et al. 2012; 
Gumy et al. 2012). 
  Biological surveillance data; behavioural surveillance data is limited (e.g. Dubois-Arber et al. 
2012; Kübler et al. 2012; Jeannin et al. 2010). 
Areas of data gaps: 
− Cost data. 
− Outcome/impact among the target population (APiS and other projects targeting FSW) 
− Structural prevention measures 
Prison inmates 
Data on the target 
population, FOPH, FSO 
    Epidemiological data is scarce and imprecise  
Data on the provision of prevention, counselling and testing in prisons (Masia et al. 2007, 
Achermann/Hostettler 2007). 
Areas of data gaps 
− Cost data. 
− Outcome/impact of BIG (controlling infectious diseases in prisons) 
Shaded cells: No data available 
 
 
Table 10: Data sources for an economic evaluation of HIV/STI prevention measures of intervention axis 3  
Intervention axis 3 
Target groups 
Input Outcome Impact Benefit Remarks 
Infected people and their 
partners 
Estimation of the size of the 
target group, FOPH, SHCS, 
forthcoming estimation by 
P. Vernazza. 
 
    Biological and behavioural surveillance data (national, regional level) (FOPH, IUMSP, e.g. 
Jeannin et al. 2010). 
Representativeness of the SHCS is unclear, SHCS concentrates on HIV and provides no 
information on the coverage of prevention activities, etc. 
Areas of data gaps: 
− Cost data. 
− Outcome/impact data on the courses for those with HIV infection and for their partner. 
− Outcome/impact data on the measures targeting doctors, medical specialists. 
− Other prevention measures, counselling facilities, campaigns. 
Shaded cells: No data available 
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6 Pilot study on the collection of cost data 
The literature analysis in section 4.1 showed that secondary data on the costs of HIV/STI 
prevention in Switzerland is scarce and rather inexact. Furthermore, research experience 
have demonstrated the difficulties to obtain such data as there are many sources (ac-
tors/organisations) that invest in HIV/STI prevention. 
In order to gain insights on the feasibility of the collection of primary cost data, we conducted 
a small pilot study. We collected cost data for "Break the Chain 2012 in Zurich". Break the 
Chain (BTC) is a prevention measure targeting men who have sex with men (MSM). This 
measure was selected because in Switzerland, MSM are affected the most by HIV and Zu-
rich is one of the regions particularly affected by HIV and other STI (see section 3.1). Addi-
tionally, the FOPH commissioned the Institut universitaire de médecine sociale et preventive 
of Lausanne (IUMSP) to conduct an evaluation of this prevention measure (Lociciro et al. 
2012a). 
6.1  Description of the prevention measure "Break the Chain 2012" 
In collaboration with its partner organisations, the FPOH (2011) is implementing an "Urgent 
Action Plan" to prevent HIV and other STI among MSM. This plan aims to prevent HIV infec-
tions during the primary infection phase, reduce the interval between infection and diagnosis 
and lower HIV transmission after diagnosis (ibid: 32 -34). A core element of this plan is the 
annual campaign "Break the Chain" (BTC) that aims to interrupt the HIV transmission chains 
among MSM.  
BTC is based on the assumption that half of all HIV infections among MSM are passed on 
during the highly infectious primary infection phase which lasts up to three months after the 
infection. The infectiousness during the primary infection phase is 20 to 100 times higher 
than later on. In this primary infection phase, the virus is 20 to 100 times more infectious than 
later on. Therefore, the virus spreads rapidly in the case of parallel sexual relationships dur-
ing this phase. BTC is a campaign of one month and calls upon all gay men to break the 
chains of infection, for example by consistently practising safer sex during this period of 
time..18
"If fewer gay men had unprotected sex during the primary infection phase, the chain of infections would 
break and the community viral load would reduce overall" (FOPH 2011: 33). 
 The following quotation of the FOPH's brochure "Sex between Men: Towards a better 
Sexual Health 2012" expresses the logic of the campaign in a nutshell:  
In 2012, the FOPH commissioned the Zurich Aids Help Organisation (ZAH)/Checkpoint Zu-
rich to implement BTC in Switzerland. The implementation of BTC concentrated on the city of 
Zurich but also comprised activities in other cities, particularly in Lausanne and Geneva. The 
campaign was directed by ZAH/Checkpoint Zurich.  
BTC uses a community approach and is thought to act as a prevention intervention of the 
community for the community. Thus, BTC requires the mobilisation of the gay community 
and the involvement of all actors of the Swiss gay scene. MSM should take an active part in 
the campaign and act in compliance with personalised recommendations to prevent any new 
infection or transmission of HIV during one month. Further, the campaign requires that the 
                                               
18  The FOPH already implemented such a campaign calling to consistently practice safer sex among MSM during a defined 
period of time in 2008 (Balthasar et al. 2008; Pluess et al. 2009). In 2008, the campaign was based on the same assump-
tions, had the same aims but called for a period of three months of safer sex among MSM and was called "Mission Possi-
ble". 
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interface between prevention, testing and treatment is guaranteed. BTC 2012 comprised 
three stages of intervention (see also Lociciro et al. 2012a: 6-7): 
 
September 2011 to March 2012:  
The FOPH developed, launched and promoted its new brochure "Sex between Men: Towards a Better Sexual 
Health 2012" (FOPH 2011). This brochure addresses MSM and provides information regarding current facts, 
developments and background on HIV and sexual health between men (FOPH 2011: 1). The FOPH commis-
sioned a consulting company (Life Science Communication AG) to support the development and dissemina-
tion and promotion of the brochure. Dissemination and promotion used the following channels: mass media 
and gay media (PR and ads), internet banners, social media and dating platforms and an information kit for 
the outreach work of the ZAH/Checkpoint Zurich. Further the campaign material (e.g. brochures, posters, fly-
ers) was distributed to VEGAS Verband Gaybetriebe Schweiz, other gay associations, the AHS and the coun-
selling centres. 
  MSM should increase their knowledge on the relevance of the primary infection phase for HIV transmission 
and know the symptoms of a primary infection. They are informed about an effective prevention strategy in 
accordance with their personal situation. 
February to April 2012 
The ZAH/Checkpoint Zurich motivated MSM to participate in the campaign (practices safer sex during one 
month, April 2012) and disseminated the prevention messages of BTC over various channels. For example: 
The (gay) press, videos, internet banners, posters, flyers, smartphone applications, outreach work, involve-
ment of VEGAS, commercial suppliers (bars, clubs).  
 MSM are informed about BTC, comprehend the aims of BTC and identify whether they are part of a trans-
mission chain or not and develop an effective protection strategy in accordance with their personal situa-
tion. They are prepared to take an active part in BTC during April 2012 to reduce HIV transmissions in the 
gay community. They participate in BTC in compliance with an effective protection strategy to prevent any 
new HIV infection or transmission during April 2012. 
Mai 2012  
The ZAH/Checkpoint Zurich launched a campaign to promote voluntary counselling and testing. Two HIV tests 
for the price of one were offered in the case of unprotected anal intercourse and for all those who wanted to 
practice sexual intercourse without a condom.  
 MSM, particularly those who suspect that they have contracted a sexually transmitted infections, use VCT 
services. 
Figure 4 presents the chain of effects of BTC 2012 that we have developed based on the 
documentation of BTC and information provided by the FOPH, the ZAH/Checkpoint Zurich as 
well as the interim report of the evaluation (Lociciro et al. 2012a). 
Following the intervention logic of BTC, the intended behaviour changes among MSM should 
result in a reduction of HIV transmission in the gay community and thereby decrease the viral 
load in this community. The sexual health of gay men should improve. The prevention of HIV 
and STI infections results in savings of treatment costs and in productivity gains.  
 
 Figure 4: Chain of effects "Break the Chain 2012" 
 
FOPH:  
Develops and 
supports the 
implements of 
the Urgent 
Action Plan 
and BCT 
2012. 
Launches and 
promotes the 
new brochure 
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men" (FOPH 
2011). 
MSM 
Increase of awareness, knowledge 
and comprehension 
MSM increase their knowledge about 
primary HIV infection, comprehend 
the intervention and are prepared to 
take an active part in BCT during 
April 2012 to reduce HIV transmis-
sions. 
 
MSM 
Behaviour change 
MSM develop an effective protection 
strategy in accordance with their 
personal situation and participate in 
BCT. They consistently practice safer 
sex at least during April 2012 and 
prevent any new HIV infection or 
transmission during April 2012. 
Men who suspect that they have 
contracted a sexually transmitted 
infection use VCT services. 
Newly diagnosed people receive 
counselling and care* 
Direct benefits 
Health care sav-
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* Counselling and care of newly diagnosed people itself is not part of BCT but is a core a prerequisite for its effectiveness. 
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6.2  The collection of the costs of the realisation of Break the Chain in Zurich 
in 2012 
The cost analysis, conducted in a societal perspective, aims to collect all costs of BTC in Zu-
rich in 2012 regardless who paid it and thus, data collections consider all involved actors. 
According to the involved actors, the development and implementation for BTC 2012 in Zu-
rich took place between September 2011 and September 2012. Thus, the collection of cost 
data concentrates on this period. We included direct as well as indirect costs while we ex-
cluded intangible costs of BTC. Intangible costs of HIV/STI prevention campaigns (utility 
losses due to the participation in a campaign) are usually not mentioned in existing economic 
evaluations (see section 4.2.1, 4.4.3). In other words, these intangible costs are not consid-
ered as important 
With respect to the direct costs, we conducted a full cost analysis including the costs for per-
sonnel, material, overhead and infrastructure. In contrast, we did not include all indirect costs 
attributable to BTC. We collected information on the voluntary work spent to support the im-
plementation of BTC. We excluded the time of end addressees (MSM) spent for the partici-
pation in BTC as well as the time of their relatives to support their participation. The time re-
sources that the end addresses and their relatives need to process the campaign's mes-
sages, to develop and comply with an effective protection strategy to avoid any infection risk, 
are considered as not very significant. Further, such costs are usually not considered in the 
international literature (see section 4). 
In a first step, we identified the involved actors. The FOPH and the ZAH/Checkpoint Zurich 
were the central actors who invested considerably in this campaign. The FOPH and the ZAH/ 
Checkpoint Zurich commissioned third parties to produce, design and diffuse campaign ma-
terials and messages. Additionally, the gay community contributed in terms of voluntary work 
and with vouchers for special offers. While the Swiss Aids Federation (AHS) also supported 
BTC the cantonal and communal administrations of Zurich were not involved. Figure 5 de-
picts the flow of resources and shows that we had to apportion the costs to be able to calcu-
late the costs for BTC in Zurich. 
Figure 5: Resource flow “BTC 2012 in Zurich” (direct costs) 
 
43 % 34 % 23% 
FOPH 
ZAH 
Personnel costs, material costs, overhead and capital costs 
Contracts with third parties 
General/ 
national 
Implementa-
tion Zurich 
Implementation 
Geneva/Lausanne 
Life Science 
Communica-
tion  
IUMSP Agencies for 
translations, 
layout. 
AHS 
The arrow between the FOPH and the AHS is dotted as the contract between the FOPH and the AHS does not earmark a 
particular amount of money for services of the AHS related to BTC 2012. We included the costs of the AHS allocated to 
BTC 2012. Details on the apportioning are given in Table 11 and 12. 
White arrows indicate that these actors/regions dispose of additional funding sources for HIV/STI prevention among MSM. 
79 % 
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In a second step, we identified the main cost components (in terms of (volunteer) activities, 
personnel, material, and overhead/infrastructure costs) and collected the cost information. 
While the costs of some components are based on invoices of the FOPH and the 
ZAH/Checkpoint Zurich, others are based on estimations provided by these actors. 
Table 11 calculates the costs spent by the FOPH for the realisation of BTC 2012 in Zurich. It 
reveals that the FOPH spent approximately 526’000 CHF for the realisation of BTC 2012 and 
the share for Zurich is estimated at 315’600 CHF. The estimation is based on the costs for 
the production of the brochure “Sex between Men” (FOPH 2011) and the costs for the devel-
opment, implementation and evaluation of BTC 2012. The former costs are not fully attribut-
able to BTC 2012 as the brochure is also used for other prevention measures. The FOPH 
spent approximately 79% of its BTC costs for services by third parties. ZAH/Checkpoint Zu-
rich received the highest amount, in order to raise the campaign. While this share of 79% is 
documented by contracts and invoices, the internal costs of the FOPH are based on estima-
tions provided by the FOPH. 
Table 11: Costs spent by the FOPH for the realisation of BTC 2012 in Zurich 
FOPH: Costs for BTC 2012    
Costs for the brochure "Sex between Men"   
Type of costs Costs in CHF Comments 
Personnel (74'233) Source: FOPH, estimation of the work time spent by the re-
sponsible staff of the FOPH  
Overhead/infrastructure (14'847) Estimation, 20 % of the costs for personnel. The personnel 
costs does not included the costs for the infrastructure etc. 
Contract with third parties   
Concept, editing, communication, promotion, 
distribution  
107'979 Source: FOPH, contracts/invoices 
Design and Layout  29'408 Source: FOPH, contracts/invoices 
Translation 8'317 Source: FOPH, invoices 
Print costs 23'418 Source: FOPH (Federal Office for Buildings and Logistic bore 
theses expenses) 
Subtotal Costs for the production of the bro-
chure "Sex between men" 
(258'202)  
Subtotal Costs of the brochure allocated to 
BTC 2012 (30%) 
(77'460) This brochure was a key element of BTC but was used for 
other prevention activities. According to the FOPH 30% 
should be attributed to BTC 2012. 
Realisation of Break the Chain 2012   
Type of costs Costs Comments 
Personnel (69'715) Source: FOPH, estimation of the work time 
Overhead/infrastructure (13'943) Estimation, 20 % of the costs for personnel. The personnel 
costs does not included the costs for the infrastructure etc. 
Contract with third parties   
ZAH/Checkpoint Zurich 286'750 Source: FOPH, Contract, 74% of the Budget 387'500  
Evaluation IUMSP 78'192 Source: FOPH, Contract 
Subtotal: Costs for the realisation of BTC 2012 (448'600)  
Total costs of BTC 2012 (526'060)  
Total costs attributable to BCT in 2012 Zu-
rich 
(315'636) Share of Zürich is calculated based on the resource alloca-
tion of the ZAH/Checkpoint Zurich, 60%, see Table 12 
This calculation does not include the costs of the FOPH to participate and present BTC at international conferences. Further, 
the costs to conduct the present cost analysis are not included. Finally, the FOPH commissioned the AHS to conduct HIV/STI 
prevention directed to this target population. Thus, the resources spent by the AHS for BTC 2012 in Zurich are likely to origi-
nate from the FOPH. 
Numbers in brackets are estimates or calculations including estimates.  
Numbers without brackets are directly derived from invoices, contracts. 
 
Table 12 presents the costs calculation of the ZAH/Checkpoint Zurich. This calculation pro-
vides the bases to apportion the share of Zurich. The main cost components are paid ser-
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vices by third parties. These services include the design, production and diffusion of cam-
paign materials and tools (e.g. website, film, banners, ads in (gay) press, smart phone appli-
cations). This amount of 336’824 CHF is documented (invoices). As BTC was the main pre-
occupation of the responsible collaborators during the campaign, the estimation for person-
nel and material seem to be fairly precise. In contrast, we added 10% for overhead and infra-
structure. This estimate is rather low. In total the ZAH spent 422’700 CHF for the realisation 
of BTC 2012 in Switzerland. The FOPH financed 68% (286’750, earmarked money for BTC, 
see Table 11) of this amount. We do not have data on the sources of remaining 32% (e.g. 
the ZAH receives funds from the cantonal and communal authority). 
Table 12 Costs spent by the ZAH/Checkpoint Zurich for the realisation of BTC 2012 in Zurich 
ZAH/Checkpoint Zurich: Costs of BTC 2012   
Type of cost Costs on CHF Comments 
 Total General/ 
national 
Zurich Geneva  
Personnel (68’406) (27’363) (27’363) (13’681) Source: ZAH, calculation of shares: 40% 
general/national, 40% Zurich, 20% Geneva,  
Materials, travel costs, 
etc. 
(9’663) (3’865) (3’865) (1’933) Source: ZAH, calculation of shares: 40% 
general/national, 40% Zurich, 20% Geneva, 
Subtotal internal costs (78’069) (31’228) (31’228) (15’6145)  
Subtotal incl. over-
head/infrastructure 10% 
(85’876) (34’351) (34’351) (17’175) Estimation, 10% of internal costs. 
Paid services by third 
parties 
336’824 110’692 145’434 80’698 
 
Source: ZAH, invoices. 
This costs cover development, design as 
well as diffusion of communication materials 
(e.g. internet, banners, ads in (gay) press, 
smart phone applications). 
Total Costs of BTC 2012 (422’700) (145’043) (179'785) (97’873)  
Costs percentages 100% 34% 43% 23%  
Apportioning of national cost (145'043) to Zurich and Geneva, Lausanne, other regions: ¼ of the national costs for other re-
gions (Bern, Bale) and of the remaining ¾ we apportioned 2/3 to Zurich and 1/3 to Geneva, Lausanne and other regions. 
Numbers are set in brackets as they are based on estimates 
 Costs in CHF Comments 
 Total share of Zurich Total share of Geneva, 
Lausanne, other regions 
 
Total Costs of BTC 
2012 
(252'306) (170'394) Estimation 
Cost percentages 60% 40%  
Numbers in brackets are estimates or calculations including estimates. 
Numbers without brackets are directly derived from invoices, contracts. 
 
Table 13 reveals that the estimate for the costs of the tests performed for free is low and 
negligible. However, it should be discussed whether the costs for the increase in test uptake 
should be included.  
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Table 13: Costs for HIV tests performed for free by the Checkpoint Zurich 
 
Checkpoint Zurich: Number of Tests and costs of tests during BTC 2012 
Type of costs Number Costs in CHF Comments 
Tests promotion, tests conducted free 
of charge by the Checkpoint Zurich 
15 (747) Costs of an HIV test: 49.80 CHF, source ZAH.  
ZAH estimated that ten to twenty of all tests performed 
among MSM (approx. 140) in May 2012 were performed 
for free. 
BTC 2012 led to an increase in test uptake by 17 % (Lociciro et al. 2012a). It is to discuss whether these costs should be 
taken into account. The data on the absolute number of the performed test in Zurich was not yet available from the evaluators 
as the final evaluation report is not yet published. 
Numbers in brackets are estimates respectively calculations including estimates.  
 
Table 14 presents the estimation of the costs spent by the AHS for BTC 2012. 
Table 14: Costs spent by the AHS for the realisation of BTC 2012 in Zurich 
AHS: Costs of BTC 2012    
Type of costs Costs in CHF Comments 
Personnel (13'418) Source: AHS, includes mainly the time spent for coordination 
meetings. 
Material (1'155) Source: AHS, includes the costs for the distributions of BCT 
campaign materials as well as some operating expense.  
Subtotal, costs of BTC 2012 excl. overhead/ 
infrastructure 
(14'573) Source: AHS 
Costs of BCT 2012 incl. overhead/infra-
structure  
(16'030) 10% for infrastructure etc. (1'457) 
Total costs attributable to BCT in 2012 Zu-
rich 
(9’618) Estimation, share of Zürich is calculated based on the resource 
allocation of the ZAH/Checkpoint Zurich, 60%, see Table 12 
Numbers in brackets are estimates respectively calculations including estimates. 
 
Table 15 reveals that the voluntary sector contributed, through voluntary work and special of-
fers, in a considerable way to the promotion of BTC 2012 in Zurich. These estimations were 
provided by the ZAH and shortly discussed with the board of VEGAS. 
Table 15: Indirect Costs, voluntary time spent for the realisation of BTC 2012 in Zurich  
Voluntary sector, only estimations for BTC in Zurich displayed 
Type of costs Number Hours 
(cumulated) 
Costs in CHF  Comments 
Volunteers ZAH 10 (300) (18'900) Estimation of the ZAH,  
Outreach ZAH 3 (95) (5'986) Estimation of the ZAH 
Gay establishments 51 (255) (16'065) 5 hrs per establishment based on informa-
tion of the ZAH and of the board of VEGAS.  
Subtotal, volunteers’ time  (650) (40'950) Wage per hrs of voluntary work: ZAH pro-
poses 60.- CHF; Zurn et al. (2001:22 ) used 
32.- CHF in 1998 according to market cost 
approach, the FOS calculates 48.9 (without 
management function) and 85.2 (with man-
agement function) per hrs of institutional vol-
untary work in the reference year 2010.  
We opted for 63.- based of the FOS wages 
(2/5 with management function, 3/5 without 
management function). 
Vouchers of the Gay establishments (3600)  (126’000) Estimation of the ZAH. This estimation is 
rather vague. Vouchers included very differ-
ent offers (drinks, meals, entries, haircuts, E-
bikes). ZAH suggested to value one voucher 
with 35 CHF. 
Total costs of the voluntary sector   166'950  
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The last table of this cost analysis consolidates the costs from the different sources. Thus, 
the costs for the realisation of BTC 2012 in Zurich are estimated to be 574’098 CHF. This es-
timation includes a considerable amount of voluntary resources. In an economic evaluation, 
the sensitivity analysis should consider that these voluntary resources are based on rather 
raw estimations (particularly with respect to the vouchers). 
Table 16: Consolidation of the costs attributable to BTC 2012  
 Total costs Share of Zurich 
 Costs in CHF Share Costs in CHF Share 
BAG (526’060) 78% (315’636) 55% 
ZAH/Checkpoint* (135’950) 20% (81’147) 14% 
AHS (16'030)  2% (9’618) 2% 
Subtotal  (678’040) 100% (406’401)  
Voluntary sector   (166'950) 29% 
Tests   (747) 0% 
Total costs of BTC 2012 in Zürich   (574’098) 100% 
* 32 % of the costs of the ZAH are included the remaining 68% are included in the costs spent by the FOPH. 
Costs are displayed in brackets as they are based on estimations. 
 
As the IUMSP has not yet finalised the evaluation of BTC 2012, we do not discuss any rela-
tion between the costs and the consequences of BTC 2012 in the present report.  
6.3  Key insights of the pilot study  
On the one hand, we were confronted with the problem of apportioning costs incurred at the 
national level for the implementation in Zurich. On the other hand, BTC did not directly in-
volve the cantonal or communal administration of Zurich and thus, we did not include any 
costs spent by these institutions. We could not obtain detailed costs data for the overhead 
and infrastructure costs of the involved actors and therefore used a discretionary rate. 
Although the involved actors supported the data collection, we needed considerable period of 
time to obtain the cost data. The actors had to compile the data sources and estimations. 
Thus, a cost analysis is a rather time-consuming task not only for the evaluators but also for 
the affected actors. 
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7  Assessment by the Surveillance Working Group 
The design of the feasibility study was discussed by the Surveillance Working Group of the 
FCSH in its meeting in October 2012.19
7.1  Delimitation: Does surveillance encompass economic evaluations?  
 In the following, we present the main points of the 
discussion. 
At the very beginning of the discussion, the question was addressed whether an economic 
evaluation and its feasibility constitute a relevant issue within the field of HIV/STI surveil-
lance.  
The Working Group emphasised that surveillance data provide insights on the epidemiologi-
cal and behavioural developments but cannot be easily linked to prevention measures. Thus, 
in order to be a meaningful tool for surveillance, an economic evaluation requires additional 
data on the causal relation between the prevention measures and its consequences. 
7.2  Conceptualisation of the key variables 
The Working Group raised major concerns about the appropriateness of a cost-benefit ap-
proach in the field of HIV/STI as it requires a quantification of the input and the conse-
quences of HIV/STI prevention measures. 
The Working Group shared the opinion that the input of a prevention measure should not be 
reduced to the money spent but should also include the efforts deployed by the communities 
and volunteers. The feasibility study should take into account that the implementation inten-
sity might vary geographically and across time.  
The (intended) consequences of HIV/STI prevention are likely to include effects that are not 
directly measureable and/or quantifiable. The question of the appropriate base line for the 
economics was raised (e.g. the number of lives saved, the appropriate monetary value of a 
life, treatment cost saved). The discussion pointed out that prevention measures might not 
only aim to prevent infections but also to increase public health in general. Furthermore, it 
was emphasised that the analysis of an infectious disease requires a dynamic model. 
Summing up, the Working Group recommended that the feasibility study should not reduce 
its perspective on quantifiable variables. 
7.3  Geographical delimitation 
The Working Group suggested considering a geographical delimitation of the economic 
evaluation. The economic evaluation could focus on regions that are particularly affected by 
HIV/STI, or could select some regions in order to realise a meaningful comparison.  
                                               
19  Roger Staub and Christine Heuer from the FOPH also attended this meeting. The members received a summary of the con-
cept of the present feasibility study for the preparation of the discussion. Kathrin Frey presented the concept at the meeting 
and Daniel Kübler chaired the discussion. 
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7.4  Focus of the literature analysis 
The Surveillance Working Group emphasised that the literature review should not be re-
stricted to economic evaluations but also include the literature on the effectiveness of 
HIV/STI prevention. It suggested restricting the literature analysis on effectiveness informa-
tion to reviews.  
Additionally the Working Group recommended to analyse how WHO, OECD, ECDC and the 
Global Fund decide on the allocation of resources in the absence of strong economic evi-
dence. 
7.5  Results of the Surveillance Working Group’s discussion 
The results of the discussion with the Working Group can be summarised as followed: The 
feasibility study and its goals are, for an economic evaluation, ambitious and should be re-
duced. It is of interest to have data on the resources spent for HIV/STI prevention in Switzer-
land that take into account the multiple actors involved at the federal, cantonal and commu-
nal level. An economic evaluation should consider that not all relevant components of the in-
put and the consequences are quantifiable. Evidence on the effectiveness of HIV/STI pre-
vention is crucial for an economic evaluation and a literature review of this strand of research 
could provide helpful insights. 
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8 Assessment by Swiss health economists 
We conducted five expert interviews with renowned health economists to assess the main 
challenges of an economic evaluation of HIV/STI prevention in Switzerland.20
8.1  General expert assessment of the potential of an economic evaluation in 
the field of HIV/STI prevention 
 The interviews 
were conducted face-to-face and tape-recorded. They concentrated on the possibilities and 
limitations of an economic evaluation in the field of HIV/STI prevention in Switzerland, the 
assessment of the topics the FOPH aims to cover with an economic evaluation as well as on 
crucial conceptual and methodical issues of such a study. 
All interviewed experts agreed on the relevance of an economic evaluation of HIV/STI pre-
vention measures in Switzerland. They shared the opinion that such an analysis is useful for 
policy-making. However, they were rather sceptical of an encompassing economic evaluation 
that covers all topics that the FOPH has formulated. 
The experts pointed out that the main challenge in this field is neither the economic part of an 
evaluation nor the Swiss context but the proof of effectiveness of the HIV/STI prevention 
measures (robust findings for the causality between the policy measures and the respective 
consequences). They emphasized that prevention effects are difficult to measure as they 
cannot be observed directly and as it is difficult or even impossible to conduct randomized 
controlled trials. They pointed out that the interventions’ effects might require some time to 
materialize and multiple factors – not only prevention interventions – influence behaviours of 
the population and epidemiological developments. The interviewees critically assessed the 
possibility of a multivariate regression model that uses mainly epidemiological surveillance 
data to estimate the effectiveness of HIV/STI prevention. 
In other words, the interviewees shared the opinion that the robustness of an economic 
evaluation highly depends on the quality of the data on the effectiveness of HIV/STI preven-
tion. As none of the interviewees had particular knowledge on existing effectiveness informa-
tion in the field of HIV/STI, they expressed rather general concerns. 
While no expert contested the potential of a CEA, CUA and CBA were disputed. The inter-
viewees shared the opinion that a CEA generates relevant information on the relation be-
tween the costs of HIV/STI prevention measures and the number of "averted infections". This 
type of analysis is useful to compare different prevention measures. It does not allow com-
parisons with other public health areas. Further, the assessment of a cost-effectiveness ratio 
of an individual measure (programme) requires a discretionary threshold. 
With respect to the CUA, the interview discussions concentrated on the approach of QALY to 
express the utility of a public health intervention. The opinions whether or not to use this ap-
proach and conduct a CUA differed: Some interviewees strongly recommended performing 
this type of analysis mainly for reasons of comparisons with other health areas. They 
stressed that a utility measure includes intangible values that are not considered in a CEA 
which measures the consequences of prevention only in terms of "averted infections". The 
interviewees in favour of a CUA using QALY emphasised that this approach predominates 
                                               
20  List with interview partners (11.9) and the interview guideline (11.10) are displayed in the appendix 
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the field of health economics. They also acknowledged its limits but stressed that the use of 
QALY within one particular health area is less problematic. They pointed to the importance of 
the measurement of the QALY to be based on surveys with infected and non-infected people 
and taking into account that treatment success might depend on the time of infection detec-
tion. A CUA has to acknowledge that QALY depend on the available treatment at a particular 
time. Future changes in treatment might affect both, the quality and duration of life. Some in-
terviewees shared the opinion that it is feasible to either gather primary data for QALY or to 
use QALY measured in other countries of Western Europe or even the USA. 
Other interview partners formulated strong reservations to this approach in conceptual and 
methodological terms. Further, they emphasised the difficulty of communicating the results of 
such analysis to policy-makers and the public. They stressed that this approach is limited to 
the area of health. Furthermore, they emphasised that this approach always activates the 
ethical questions of the monetary value of life: How do we assess the ratios of cost to QALY 
saved? 
All interviewees shared the opinion that a CBA would require a high level of extra efforts to 
monetise all consequences and to conduct a "willingness-to-pay (WTP)" study. In contrast, 
they assessed the added value of such an analysis quite differently. Interviewees clearly pre-
ferring a CUA attributed no additional value to a CBA. In their view, methodological concerns 
together with the difficulty of communicating the results of a CBA outweigh its advantages. 
Interviewees in favour of a CBA stressed that only this type of economic evaluation takes into 
account the preferences of the (affected) population(s) and provides an assessment whether 
the benefits of a particular policy measure equal or outweigh its costs. These interviewees 
also acknowledged that a CBA multiplies the complexity of the delimitation of the costs (in-
creasing the problematic of double counting of some costs or benefits). 
To sum up, this spectrum of opinion highlights that the conceptualisation and measurement 
of intangible values (individual pain and suffering) are much contested. In contrast, the inter-
viewees well agreed on the calculations of savings in terms of medical care costs and pro-
ductivity (reduced morbidity and mortality). One interviewee argued that these economic sav-
ings are assumed to be considerable in the case of HIV. Therefore, the measurement of indi-
vidual suffering and pain related to HIV is not absolutely necessary and can be omitted not 
only due to conceptual and methodological concerns but also for pragmatic reasons. Further, 
findings about the suffering of the infected individuals and their relatives could be presented 
convincingly without a quantification and monetisation. 
8.2  Expert assessment of the study's topics as formulated by the FOPH 
In general, the interviewed experts largely agreed in their assessments of the study's topics 
the FOPH has formulated to guide this feasibility study (see section 1.1). 
The interviewed experts welcomed an economic evaluation from a societal perspective that 
includes all costs and consequences of HIV/STI prevention measures, no matter who pays or 
benefits. They emphasised that the analysis should aim to realize such a perspective but 
might exclude some costs or consequences. Some costs and consequences might turn out 
to be negligible or strong feasibility constraints hamper their inclusion (e.g. indirect costs of 
the volunteers or participants of a specific prevention intervention, intangible benefits of 
averted HIV/STI infection). 
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With respect to the costs of the prevention measures, they emphasized the relevance of in-
cluding not only the resources spent by the FOPH but also collecting information on the re-
sources spent by other public and private actors. They shared the opinion that the collection 
of such cost information is labour-intensive and requires enquiries of the people in charge. 
Furthermore, they emphasized that it might be difficult for the people in charge to estimate, 
for example, personnel resources spent for particular prevention measures (e.g. axes). The 
interviewed experts pointed out that the volunteer time is at least conceptually a relevant 
category. They had no firm opinion on whether this cost category (opportunity costs) needs 
to be included in an economic evaluation of HIV/STI prevention measures. The interviewees 
shared the opinion that it is relevant to produce cost data that show how many resources are 
spent for the different axes of HIV/STI prevention.  
With respect to the consequences of the prevention measures, they pointed out that a socie-
tal perspective would require considering all consequences of the HIV/STI prevention meas-
ures. In particular, they mentioned any savings resulting from a prevention measure in terms 
of medical costs, productivity and individual suffering. 
All interviewees shared the opinion that the question of where HIV/STI prevention resources 
(efforts) are spent most effectively is crucial. A comparison between the three intervention 
axes of the NPHS would provide relevant information for the formulation of HIV/STI policy. 
The interviewees agreed that it is important to understand the relation between the costs and 
the achieved effects within a particular target group (The relation is moderated by the group 
size and the prevalence of HIV/STI). In this respect, they also welcomed the aim to calculate 
the optimal allocation of prevention resources among the three intervention axes. Some ex-
perts pointed out that the interpretation of such a calculation should acknowledge that it is 
not known how the relation between policy (efforts/costs) and behaviour changes (epidemi-
ological changes) performs when efforts are increased.  
Further, the interviewed experts pointed out that such an analysis requires good evidence for 
all prevention measures and thus, it is related to a high effort of research. Additionally, the 
interviewees highlighted the problematic of interactions between the axes. They raised con-
cerns whether the effects of the prevention measures of the axes can be isolated (problem-
atic of delimitation/attribution; e.g. the LOVE LIFE campaign is addressed towards the gen-
eral population, but the risk populations are also part of the general population). 
In contrast, the interviewed experts questioned the feasibility of a separate analysis for the 
resources spent by the FOPH. Such an analysis is only appropriate when the input of the 
FOPH is attributable to particular consequences. The experts strongly questioned the possi-
bility of isolating the particular contributions of the FOPH to the effects of the prevention 
measures. Several interviewees pointed out, that such an analysis is only possible if the 
FOPH has financed particular prevention measures entirely and if the effects of these meas-
ures can be separated from the effects of other measures implemented in the same time pe-
riod. Some experts mentioned that scenario analysis might be helpful in this respect. Others 
pointed out the relevance of knowing whether the cooperation between the FOPH and its 
partners functions in an effective and efficient way.  
The interviewees emphasised that an economic evaluation constitutes one particular source 
of information in a decision-making process and should always be complemented with other 
information, and in particular with ethical considerations. Some interviewees highlighted that 
an economic evaluation usually neglects considerations of equity.  
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8.3  Expert recommendations  
In a nutshell, the interviewed experts recommended to lower the ambitions and to start with a 
concrete, reduced study focus. If such a study reveals useful results, further studies can be 
conducted subsequently. Several interviewees shared the opinion that it is worth to know 
how resources are allocated for HIV/STI prevention and how much HIV/STI costs the society 
in terms of medical costs and productivity losses. 
• The analysis should concentrate on the comparison of policy measures (intervention 
axes). 
• The analysis should take into account direct as well as indirect costs and benefits. 
Voluntary sector could be neglected if it contributes less than 2%. 
• The interviews are not conclusive whether or not intangible consequences should be 
considered.  
• While the results are considered being very useful for policy decisions within the field 
of HIV/STI, some interviewees warned that the results might not help to justify 
HIV/STI prevention spending against other areas. 
• Such economic information should not be the only decision criteria but serve as addi-
tional input. 
• The realisation of an economic evaluation is costly. 
• Data sources in Switzerland are fragmented. 
• Discounting costs and consequences should be done as it is state of the art in the 
field of economic evaluation (rate of 3% or 3.5%). 
• Sensitivity analyses are considered as very important (probability analysis). 
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9 Synthesis and concept for an economic evaluation of HIV/STI 
prevention measures in Switzerland 
In this final section, we first present the synthesis of the findings on the feasibility of an eco-
nomic evaluation of prevention measures in the field of HIV/STI prevention. Thereafter, we 
concretise the concept for a feasible economic evaluation. 
9.1  Main findings 
In the following we synthesise the findings on the questions 1 to 4 of the present feasibility 
study, while questions 5 and 6 are answered in the last sections of this report. 
1. What is the scientific state of the art in this field? 
Generally, economic evaluation is seen as an instrument to generate policy relevant informa-
tion on the efficient allocation of resources in the field of public health and more narrowly in 
the field of HIV/STI. The current practice of international organisations reveals that economic 
evaluations do not enjoy a very high profile; documents that focus primarily on this type of 
evaluation are rare. The literature review shows that the economic evaluation of HIV/STI pre-
vention continues to be a topic of scientific interest. However, the majority of the studies re-
viewed here examined single interventions. We found only two analyses dealing with western 
countries (namely the USA) and covering prevention measures of all three intervention axes 
of the NPHS (Cohen et al. 2004, 2005). Thus, economic evaluations dealing with multiple 
prevention interventions do not (yet) represent a common approach.  
Cost-utility analyses using QALY dominate the field. The analyses are most frequently con-
ducted from a societal perspective including all costs and consequences of a HIV/STI pre-
vention measure. Study designs included anything from randomized control trials to prospec-
tive models21
There are well-recognized limitations of economic evaluation of HIV/STI prevention and in 
particular with respect to their comparability. The most fundamental concerns concentrate on 
the measurement of the effectiveness respectively the mathematical models of HIV trans-
mission to estimate the epidemiological impact of the prevention interventions.  
 that estimate the cost-effectiveness of (hypothetical) prevention interventions. 
Discounting and sensitivity analyses are state of the art. The costs of an intervention were 
often categorised into personnel, material and overhead costs, while participant and volun-
teer costs were rarely accounted for. QALY and “infections prevented” were the most com-
monly used measures for the utility of HIV/STI prevention interventions effects. Mathematical 
models are used to convert self-reported behavioural changes (e.g. increases in condom use 
or decrease in needle sharing) resulting from the intervention into an estimate of the number 
of infections averted.  
                                               
21  E.g. Juusola et al. (2011) use a dynamic model of HIV transmission and progression to compare the cost-effectiveness of 
alternative testing strategies with the next twenty years, from 2009 to 2029. Gillespie et al. (2012) used a dynamic model to 
estimate the potential cost-effectiveness of opportunistic screening for Chlamydia in Ireland that had not yet introduced this 
intervention. 
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2. Availability of data on the costs (input) spent for HIV/STI prevention in Switzerland, 
potential of secondary analyses and possibility of primary data collection? 
While there is a lack of pre-existing data and therefore no potential for secondary analyses, 
the presented pilot study on the costs of the realisation of “Break the Chain” 2012 in Zurich 
showed that it is feasible to collect such data at a reasonable evaluation effort. However, 
such an analysis requires a considerable contribution by the actors involved in the realisation 
of the respective measures.  
Any assessment of the economic costs of HIV/STI prevention should consider direct as well 
as indirect costs (in terms of volunteer work). Further, it is important to include the local ac-
tors who are responsible for the realisation of HIV/STI prevention. Field research should be 
guided by an elaborated cost data collection protocol. Such a protocol defines the necessary 
cost information (e.g. categories) and aims to ensure good quality and comparability of 
HIV/STI prevention cost data. 
3. Availability of data on the consequences of HIV/STI prevention in Switzerland, po-
tential of secondary analyses and possibility of primary data collection? 
The availability of data on the consequences (effects) of HIV/STI prevention is fragmentary. 
Data on the chain of effects, that investigates the relation between the input and the conse-
quences (outcome/ impact) of a prevention measure, is rather scarce. Surveillance data is 
available but it does not cover all relevant target populations. Furthermore, data on other STI 
than HIV is even more limited.  
4. What are the implications and challenges for an economic evaluation of HIV/STI 
prevention in Switzerland? 
Expert interviews and discussions with the Working Group Surveillance showed that an eco-
nomic evaluation would be welcomed in general. The main concerns relate to the difficulties 
to conceptualise and measure the effectiveness of HIV/STI prevention. Some of the experts 
fear that such an analysis might end up in concentrating on the consequences that are easily 
to quantify and neglecting other relevant consequences. 
Furthermore, the fragmentation and decentralisation of data sources, the multilevel setting as 
well as the involvement of various actors in prevention activities increase the effort required 
to perform an economic evaluation.  
The co-operative approach adopted in the implementation of the NPHS makes it impossible 
to reliably attribute achieved consequences to a selected single actor. 
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9.2  Requirements of the FOPH on an economic evaluation of HIV/STI preven-
tion in the light of the findings of the present feasibility study 
In the following, we critically assess the topics the FOPH aims to cover with an economic 
evaluation and formulate recommendations on the contents of an economic evaluation. 
We recommend dismissing the separate estimation of the efficiency of the resources 
spent for HIV/STI prevention by the FOPH for reasons of feasibility.  
The expert interviews revealed that a separate estimation of the efficiency of the FOPH re-
sources spent for HIV/STI prevention is hampered mainly due to the problem of attribution. 
We share this assessment as the NPHS and its measures are implemented through the co-
operation of multiple actors. Several actors are involved in the realisation of prevention 
measures of more than one intervention axes. The cooperation and funding take place 
across the axes. Therefore it is hardly possible to link the consequences of the cooperative 
realisation of the NPHS to the individual actors in a meaningful way. Thus, we recommend 
dismissing this topic for reasons of feasibility. 
We recommend not opting for a cost-analysis instead of an economic evaluation of 
the consequences of the NPHS. 
Although expert interviews revealed that a cost analysis should be considered as an alterna-
tive or first step to obtain more economic information on HIV/STI prevention in Switzerland, 
we argue that such an analysis is not worth conducting at least in its pure from.22
We recommend that any comparisons of the intervention axes of the NPHS 2011-2017 
should acknowledge the different goals of these axes. 
 Such an 
analysis provides no information on the efficiency of the resource allocation. However, it 
could be of interest to investigate the HIV/STI prevention resource flow within the Swiss mul-
tilevel setting. Such an analysis would include the outcome of the NPHS among the partners 
of the FOPH. In other words, it investigates how the partners allocate the resources to the 
different prevention measures (activities per axes of intervention): Is the FOPH able to direct 
the resource allocations in the intended ways of the NPHS?  
While the expert interviews revealed no major concerns related to the comparison of the in-
tervention axes of the NPHS 2011-2017, we would like to point out that such a comparison is 
not as unproblematic as it seems. These axes of intervention not only differ with respect to 
the target populations but also with respect to the goals (intended consequences) and the 
emphasis placed on the prevention of HIV/STI infections (FOPH 2010: 93-105). Thus, it 
might be inappropriate to measure the effectiveness of the intervention axes with the same 
variables (indicators). While the intervention axis 1 places more emphasis on an increase of 
the awareness related to issues of sexual health as well as the reduction of HIV/STI infec-
tions and unwanted pregnancies, intervention axis 2 clearly concentrates on HIV/STI preven-
tion. This problematic is accentuated with respect to the intervention axis 3 that targets in-
fected people and their partners. In this axis, prevention aims at HIV-infected persons being 
alerted not to pass on the virus and uninfected partners being motivated not to become in-
fected (ibid: 93). 
                                               
22  Although the study of Zurn et al. (2001) on the social cost of HIV was and still is of relevance, we think that an extended up-
date of this study should not be considered as an alternative to an economic evaluation. 
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These differences between the intervention axes do not render a comparison impossible but 
any comparative analysis has to acknowledge them. 
We recommend that any comparisons within the intervention axes should take into 
account the differences in goals and in the ways of influence of those prevention 
measures targeting structural conditions and those directly targeting individual be-
haviours of the end addresses. 
The NPHS not only aims to directly influence the sexual behaviour of the Swiss population 
and particular target groups but also to improve structural conditions that support and em-
power the Swiss population to exercise their sexual rights and maintain or improve their sex-
ual health (FOPH 2012:9). The improvement of structural conditions should ultimately con-
tribute to an improvement of the sexual health of the Swiss population (decrease of HIV/STI 
infection and unwanted pregnancies). These indirect ways of influence are more complex 
and might require more time to operate than direct behavioural interventions. Thus, any eco-
nomic evaluation has to take into account these differences in the intervention logics. 
9.3  Concept for an economic evaluation of HIV/STI prevention measures  
In this section we present two alternative concepts for the realisation of an economic evalua-
tion of HIV/STI prevention measures and thereby answer the questions 5 and 6 of the pre-
sent study.  
5. Which HIV/STI prevention measures should be considered? 
6. How should a feasible economic evaluation be designed? 
Based on the above presented findings, we have the opinion that there are two feasible but 
very distinct alternatives: Alternative A consists in opting for a mathematical modelling study 
that estimates the efficiency of the NPHS 2011-2017 and performs scenario analyses with 
respect to the mix of prevention measures (intervention axes). In contrast, alternative B opts 
for a step-by-step approach and proposes to start with very restricted but concrete economic 
evaluations. Table 17 shows how these alternatives cover the topics that the FOPH is inter-
ested in: 
Table 17: Overview on the proposed alternatives 
Questions raised by the FOPH Alternatives Remarks 
 A B  
The overall cost-benefit-relation of HIV/STI 
prevention in Switzerland? Cost-benefit rela-
tion of the three axes of intervention? 
  A comparison between the axes of intervention has to take 
into account the differences in goals as well as in the ways of 
influence (chains of effects). 
Cost-benefit relation of the FOPH resources 
spent for HIV/STI prevention? 
  Not feasible 
Optimal allocation of prevention measures 
(resources) among the three axes of inter-
vention of the NPHS? 
   
Cost-benefit-relation of prevention measures 
for MSM in Zurich? 
  This alternative could analyse further prevention measures or 
the resource flows, but does not cover the entire NPHS. 
 
None of these two alternative covers all the topics the FOPH is interested in. Further, the al-
ternatives differ in fundamental aspects such as research aims and questions. As we think 
the FOPH first needs to discuss and decide on these two fundamental alternatives, we have 
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not elaborated a detailed evaluation design. Instead, we outline these two alternatives in 
greater details in the following. 
Alternative A: comprehensive model estimating the efficiency of the NPHS 2011-2017 
Alternative A concentrates on the estimation of the overall efficiency of the NPHS as well as 
on the comparison between its axes of intervention. This alternative could additionally in-
clude scenario analyses to find “the” optimal allocation of resources for prevention measures 
among the three axes of intervention. In contrast, this alternative does not include an eco-
nomic evaluation of HIV/STI prevention for MSM in Zurich. 
Such a comprehensive perspective that covers multiple prevention interventions is not well 
established in the international literature. In contrast, we found only two articles that compare 
several interventions of the three intervention axes (Cohen et al. 2004, 2005). This alterna-
tive A, respectively the FOPH topics, is clearly informed by the work of Cohen et al. (2004, 
2005). Cohen et al. (ibid) developed a tool using mathematical models to estimate the rela-
tive cost-effectiveness of 26 HIV prevention interventions including biomedical interventions, 
structural interventions, and interventions designed to change risk behaviours of individuals. 
This tool aims to help local communities to maximise the impact of their HIV (but not STI) 
prevention resources. The analysis calculates the cost-effectiveness ratio based on the total 
cost of an intervention divided by the number of HIV cases prevented (= costs per HIV case 
prevented). The number of prevented HIV cases was estimated with mathematical models 
using secondary data on the group sizes, HIV prevalence, the sexual behaviour (number of 
partner, frequency of sex acts) and parameters measuring the effectiveness of interventions 
(such as changes in condom uses, number of sex partners) (Cohen et al. 2004: 1406). 
Cohen et al. (2004, 2005) developed a practical tool (spreadsheet) for community planning 
groups and health departments.23
We suggest that such an analysis elaborates an enhanced mathematical model that aims to 
cover the NPHS 2011-2017 as comprehensively as possible. The modelling study should 
use the available Swiss data (see section 5). When Swiss data on the effectiveness of a par-
ticular HIV/STI prevention measures is not available, the analysis should be informed by 
secondary data from other western countries. However, this might not be meaningful with re-
spect to the costs of an intervention. Thus, alternative A might require a rough estimation of 
the costs of the prevention measures based on primary data. 
 We would like to point out that we do not know whether the 
tool of Cohen et al. was actually used by local communities in the USA or elsewhere. Fur-
ther, this tool has three general limitations with respect to its applicability to the Swiss con-
text. First, it concentrates on HIV while the NPHS includes other STI as well. Second, it is 
developed for the local level and does not take into account different levels. As the Swiss re-
gions are differently affected by HIV/STI it would be important that the model could deal with 
this epidemiological differentiation, particularly with respect to the calculation of the optimal 
mix. Third, the effectiveness data used by Cohen et al. (2004) mainly originates from studies 
respectively interventions conducted before 2000. This data does not reflect the changing 
nature of the HIV/STI epidemic of the last fifteen years. A Swiss analysis should be informed 
by more recent effectiveness data. 
We are not totally convinced that such a mathematical modelling study is worth the research 
efforts. On the one hand, the potential of such an analysis is reduced by the availability of 
                                               
23  http://www.rand.org/pubs/drafts/DRU3092.html 
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data and thus, the uncertainties are manifold. Some of the data gaps and limitations might be 
resolved in the near future. The timing of this alternative should take into account these de-
velopments. On the other hand, the potential of such a mathematical modelling study to in-
form policy-makers is limited due to its focus on averted infections. Cohen et al. (2004: 1410) 
show that the factors which most strongly determine the cost-effectiveness of programs are 
the HIV prevalence in the target population and the cost per person reached by the interven-
tion. Thus, interventions in a population group with a low HIV prevalence need to have an ex-
tremely low price per person reached to be cost-effective. Interventions that target popula-
tions that have a high prevalence of HIV can be cost-effective even when the implementation 
cost per person reached is considerable. This means for instance that any intervention tar-
geting the youth, e.g. school children, are not likely to be cost-effective primarily because the 
HIV prevalence in this groups is very low (ibid). Of course, an economic evaluation should 
not be considered as decisive; other critical factors to be considered are political, ethical or 
social issues. Thus, it could be argued that the added value of such an economic evaluation 
does not very much exceed an expertise based on evidence available to date. Table 18 pro-
vides an overview on this alternative of an economic evaluation of HIV/SIT prevention meas-
ures in Switzerland. 
Table 18: Overview on alternative A 
Alternative A: Mathematical modelling study about the cost-effectiveness of the NPHS 
Study aims Estimation of the cost-effectiveness of the NPHS and of its intervention axes. This alternative aims to 
cover the NPHS as comprehensive as possible (including all relevant target population respectively pre-
vention measures). 
Questions • Which is the overall cost-effectiveness-relation of HIV/STI prevention in Switzerland? 
• Which are the cost-effectiveness relations of the three axes of intervention of the NPHS? 
• Which is the optimal allocation of prevention measures (resources) of the NPHS? 
Design Mathematical modelling study 
Main data sources Mainly secondary data from existing outcome evaluations and surveillance data. Additionally, secondary 
data from other western countries might inform the analysis when Swiss data is missing. 
 
Alternative B: Stepwise approach through selective economic evaluations 
Alternative B aims to produce empirically robust findings on the efficiency of selected preven-
tion measures. Thereby, the comprehensive perspective is abandoned for a stepwise ap-
proach. On the one hand, the majority of the interviewed experts recommended a stepwise 
approach and a reduction of the research topics. On the other hand, the presented literature 
analysis showed that clearly focussed studies on particular prevention intervention dominate 
the field. 
The selection of prevention measures should follow the principle of effectiveness: Economic 
evaluations should concentrate on the areas where the results of the economic evaluation 
are most likely to have an impact on the policy (Widmer et al. 2001: 89). In areas where a 
policy change is not considered as feasible for other, e.g. ethical or political reasons, it is not 
worth to conduct an economic evaluation. Additionally, the selection of prevention measures 
should consider the availability of data. 
A stepwise approach that starts with one to three rather small economic evaluations facili-
tates a substantial involvement of the commissioners, the potential users of the findings of 
the economic evaluation(s) as well as the stakeholders such as prevention and medical spe-
cialists. On the one hand, narrowly defined evaluation objects (particular policy measures 
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implemented in a defined geographical area) also delimitate the addressees of the evaluation 
itself. On the other hand, the stepwise approach is open-ended and offers the possibility to 
(re-)direct the study based on interim findings and discussions with key users. In this way, 
policy-makers (programme managers) receive more opportunities to bring in their perspec-
tives and needs for policy relevant economic information. Policy-makers also progressively 
get to know what economic evaluations can contribute with respect to policy decisions. How-
ever, the disadvantage of this approach is, of course, that it provides no ultimate directions 
how to allocate the resources to the three intervention axes. 
Although alternative B should draw as far as possible on available secondary data, the pro-
duction of primary data is part of this alternative too. 
In line with the FOPH research interests and according to insights gained from the expert in-
terviews, we suggest that alternative B should first concentrate on the topic of HIV/STI pre-
vention targeting MSM in Zurich. The very first step should concentrate on the prevention 
campaign “Break the Chain”. The cost data generated in the present feasibility study should 
be used to perform an economic evaluation based on the effectiveness data produced by the 
IUMSP (Lociciro et al. 2012a). The results of this economic evaluation should be discussed 
with the main actors. In a second step, other prevention measures targeting MSM in Zurich 
could be investigated. In a further or parallel step, this alternative could either opt for an eco-
nomic evaluation on prevention measures targeting another risk group, investigate preven-
tion measures targeting MSM in a distinct geographical area (e.g. Geneva and Lausanne) or 
concentrate on the resource flows of HIV/STI prevention in Switzerland and thereby focus-
sing on the outcome of the NPHS among the partners of the FOPH. The latter analysis in-
vestigates how the partners allocate the resources to the different prevention measures: Is 
the FOPH able to direct the resource allocations in the intended ways of the NPHS? Such an 
analysis was less present in the interviews and the investigated literature.  
This alternative B abandons the aim to cover the entire NPHS in one evaluation study but 
could generate information how to further develop economic data collection and analyses in 
the field of HIV/STI. Table 19 provides an overview on this alternative. 
Table 19: Overview on alternative B 
Alternative B: Stepwise approach to produce empirical findings on the efficiency of selected prevention measures 
Study aims Alternative B aims to produce empirically robust findings on the efficiency of selected prevention meas-
ures. It aims to further develop economic data collection and analyses in the field of HIV/STI. 
Questions • Which is the cost-effectiveness relation of Break the Chain in Zurich? 
• Which is the cost-effectiveness relation of prevention measures for MSM in Zurich? 
 
Additionally, this alternative could deal with the following questions. Alternative B should not aim to 
cover all this questions but select the most relevant and perform a stepwise approach. 
• Which is the cost-effectiveness of prevention measures for MSM in Geneva and Lausanne? 
• Which is the cost-effectiveness of prevention measures for other selected risk groups in Zurich? 
• Which are the flows of resources in the field of HIV/STI prevention in Switzerland (NPHS)? Is the 
FOPH able to direct the resource allocations in the intended ways of the NPHS? 
Design Empirical analysis of the cost-effectiveness of selected prevention measures; complemented by mathe-
matical modelling if necessary. 
Main data sources Collection of primary data particular on the cost of the selected prevention measures and on the effec-
tiveness when secondary data is not sufficient. 
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11 Appendix 
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health promotion (including cost analysis) 
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11.2  Search strategy literature analysis 
Search of documents of the international organizations 
Organization CDC, ECDC, OECD WHO, World Bank and UNAIDS. 
Sources/database Official homepages of the organizations, September/October 2012. 
Type of documents • Guidelines and recommendations on economic evaluation in the field of pub-
lic health. 
• Guidelines and recommendation on the collection and analysis of cost data. 
• Scientific studies (reports) comprising an economic evaluation of HIV/STI 
prevention intervention(s). 
Analysis • Guidelines and recommendations are analyzed qualitatively. The feasibility 
study will refer and summarize the relevant documents. 
• Scientific studies are analyzed with the scheme presented below. 
 
General search strategy for economic evaluations of HIV/STI prevention: scientific studies and reviews 
Languages English, German 
Databases • NHS EED National Institute for Health Research, Economic Evaluation Data-
base, http://www.crd.york.ac.uk/CRDWeb/AboutNHSEED.asp 
• Web of Science (http://apps.webofknowledge.com) 
• ERIC Education resources information center http://www.eric.ed.gov 
• Campbell library http://www.campbellcollaboration.org 
• Cochrane library http://www.cochrane.org 
Search terms 
(if possible, search in Title, 
Abstract and Key Words) 
(HIV OR HIV/AIDS OR AIDS OR HIV/STI OR STI OR HIV/STD OR STD) AND prevent* 
AND (cost* OR spend*) AND (effective* OR consequence* OR utilit* OR benefit* OR 
efficiency Or (economic AND evaluation)) 
Search Period 01/01/1996 – today (1996 because of the introduction of ART) 
Other sources Studies found by other sources (e.g. bibliographies of systematic reviews, or of identified 
studies) are also taken into account. 
Type of documents • Scientific studies 
• Reviews 
Inclusion criteria It is an economic evaluation (CEA, CCA, CUA or CBA) of one or more prevention meas-
ure(s) or a review of economic evaluation in the field of HIV/STI. 
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Detailed search strategy and results 
 NHS EED – National Health 
Service Economic Evalua-
tion Database 
WoK –Web of Knowledge 
ERIC – Education Re-
sources Information 
Center 
Search string (HIV OR HIV/AIDS OR AIDS 
OR HIV/STI OR STI OR 
HIV/STD OR STD) AND pre-
vent* AND (cost* OR spend*) 
AND (effective* OR conse-
quence* OR utilit* OR benefit* 
OR efficiency Or (economic 
AND evaluation)) 
Titel = ((cost* OR spend*) OR 
(effective* OR consequence* 
OR utilit* OR benefit*OR effi-
ciency) OR (economic and 
evaluation)) AND 
Topic = (HIV OR HIV/AIDS 
OR AIDS OR HIV/STI OR STI 
OR HIV/STD OR STD)  
AND 
Topic= (prevent*) 
AND 
Topic= (effective* OR conse-
quence* OR utilit* OR benefit* 
OR efficiency)  
AND 
Topic= (cost* OR spend*) 
(HIV OR HIV/AIDS OR 
AIDS OR HIV/STI OR STI 
OR HIV/STD OR STD) 
AND prevent* AND (cost* 
OR spend*) AND (effec-
tive* OR consequence* 
OR utilit* OR benefit* OR 
efficiency Or (economic 
AND evaluation)) 
Search for “any field” Title, Topic (see string) “Keywords (all fields)” 
Publication Date 01/01/1996 - 02/10/2012 1996 - 2012 1996-2012 
Type of documents 
any 
Article or review or book or 
other 
any 
Number of results 456 671 29 
Number of results in-
cluded (preliminary). 
Results are overlap-
ping (same studies are 
found in more than 
one database) 
100 146 8 (access to 7) 
Adjusted number of 
included studies 
108 
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11.4  Consequence measures discussed in the literature of International Or-
ganisations 
Main consequence measures discussed in the literature of International Organisations 
Outcome 
measure 
Strengths Weaknesses 
Quality-
Adjusted Life 
Years (QALY) 
• Captures changes in morbidity as well as mortality 
• This allows direct comparison across a variety of 
interventions. 
• Quantity and quality effects combined in one 
measure 
• Quality of life estimates for diseases in young chil-
dren are virtually non-existent and the appropriate 
methodology for doing this is subject to debate 
• Can take many different forms, depending on the 
methods used to estimate the weights 
Disability-
adjusted life 
years (DALY) 
gained 
• Cross-sector, -programme and -intervention com-
parisons are possible. 
• Morbidity and mortality effects combined in one 
measure. 
•Can include indirect consequences such as cases 
treated and/ or prevented. 
• Ability to assess impact of combined clinical man-
agement and prevention strategies. 
• Based on subjective measures of disability. 
• Calculations differs from study to study 
• Derived from and dependent on the primary out-
come of the intervention. 
• Debate over their validity. 
Infections 
averted  
• Comparisons across different prevention strategies 
are possible. 
• DALY can be derived easily with adequate informa-
tion on mortality and life expectancy. 
• Unless measured through randomized controlled 
trials, may need sophisticated modelling to assess 
impact on general population. 
• May not include indirect consequences of interven-
tion. 
Healthy-Years 
Equivalents 
(HYEs) 
• values lifetime health paths instead of individual 
health states. At least in theory, it can capture more 
accurately the true preferences of individuals. (World 
Bank 2004: 11) 
• Very challenging to execute 
Sources: UNAIDS 1998, 2000b; World Bank 2004; authors’ editing. 
 
Other consequence measures discussed in the literature of International Organisations 
Outcome measure Strengths Weaknesses 
Condoms distributed or sold 
numbers receiving educational 
material 
numbers tested/screened 
… 
• Ease of collection, these measures are often 
part of routine monitoring of programmes. 
• Reflects operational efficiency of programme. 
• Can identify most efficient method of delivery. 
• No measure of impact on HIV transmis-
sion. 
• Does not account for variations in popu-
lations’ HIV seroprevalence. 
• Gain achieved may not reflect real 
change in impact. 
Numbers educated or coun-
selled 
cases detected (through screen-
ing and counselling) 
• same as above plus 
• may give some indication of impact, even 
though final health status unknown. 
Sources: UNAIDS 1998, 2000b; World Bank 2004; authors’ editing. 
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11.6  Codebook of the literature analysis 
1st level 
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Year of Publication (YoP) Format: YYYY (auch: YYYYa) YoP 
Country of affiliated insti-
tution (1st author) 
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tralia = AUS, New Zealand = NZ, ….) Country_author 
Focus of the Study Variable 
General focus 
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2 STIs in general (or two or more) 
3 HIV and STI (if only one STI => GenFocSTI) 
4 specific STI (=> GenFocSTI) 
5 other  
 
0 no information/unknown/not identifiable 
99 unclear to coder 
GenFoc 
Focussed STI If GenFoc=(3 or) 4 , enter name of STI here.  GenFocSTI 
Target groups 
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tion + patients; “GenPop_incl_young” = Gen. pop + patients + young 
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2 MSM (also former 12: young MSM and “MSM inmates”) 
3 FSW 
4 MSW 
5 HIV positive people (see also variable “InfectedP_Part” = infected 
people and partners) 
6 migrants 
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8 Injecting drug users 
9 Men 
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12 Young MSM  (=2) 
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Create new for every new type of TG 
Target groups recoded 
General population + patients GenPop_rec 
Gen. pop + patients + young people GenPop_incl_young 
infected people and partners InfectedP_Part 
Type of interventions 
1 Counselling / education / information (individual and/or group), also 
other not more specifically defined behavioural interventions 
intv 
2 Partner notification 
3 male circumcision 
4 Voluntary Counselling and Testing (VCT) 
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5 Street outreach 
6 Community mobilization/outreach 
7 Condom availability / distribution (also female condom) 
8 Needle/syringe exchange/harm reduction/supervised injection facili-
ties/treatment of addiction 
9 Mass media campaign 
10 School-based education. Other youth oriented projects (if not more 
specifically defined) 
11 Screening and/or Testing (eg universal, school-based, at clinics, 
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12 Screening and/or Testing of pregnant women 
13 peer counselling/education/outreach (eg also opinion leader) 
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16 STI treatment 
90 other (describe in INTV_string) 
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Focus of the Study Variable 
Country / Region of 
evaluation 
1 Western Europe / North America / Australia, NZ 
2 Eastern Europe 
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4 Latin America 
5 Asia 
6 international 
7 other (eg >1 region. Specify in “Country Name”) 
0 no information/unknown/not identifiable 
99 unclear to coder 
CountryRegion 
Country Name string CountryName 
Period of data collection 
Start Year of data collection YYYY Period_data_coll_start 
End Year of data collection YYYY Period_data_coll_end 
Time perspective 
1 retrospective 
2 prospective 
3 other 
 
0 no information/unknown/not identifiable 
99 unclear to coder 
Time_persp 
Basis of comparison / of 
economic assessment 
1 on/off (also if >1 intv but as programme/mix/a whole. Also reviews) 
2 one type in diff. variations 
3 more than one type 
4 (prevention interventions ) treatment 
5 other 
 
0 no information/unknown/not identifiable 
99 unclear to coder 
Basis_comparison 
Study design (to meas-
ure the effect/causality) 
Before/after measurements 0 no / 1 yes  studes_befaft 
Control and experimental group 0 no / 1 yes  studes_contrexp 
Randomized procedure 0 no / 1 yes  studes_random 
Review 0 no / 1 yes  studes_review 
Consequences Variable 
Measurement of the ef-
fects 
1 infections prevented (HIV, STI) 
effect (1, 2, 3, 4, ..) 
 
2 decrease in risk behaviour 
3 increase in prevention knowledge 
4 DALYs gained 
5 QALYs gained 
6 Life years gained (LYG) 
7 Secondary infections averted 
8 Averted costs of (future) treatment 
9 deaths averted 
10 STI case treated 
90 other 
Create new for every new type of effect 
*: 0 no information/unknown/not identifiable ; 99 unclear to coder 
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2nd level 
Additional formal categories Variable 
Main question/objective/aim of study string mainquest 
Time frame/period of study (not data) Start Year YYYY Study_tf_start End Year YYYY Study_tf_end 
Type of economic evaluation (as named by 
study) 
1 CEA 
2 CCA 
3 CUA 
4 CBA 
90 other 
91 none mentioned 
Type_econeval 
Costs 
Perspective 
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type of costs 
collected) 
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including the private sector, the public sector and private consumers) 
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4 private sector and/or consumers (costs incurred by private sector and/or private 
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90 other (-> string) 
91 none mentioned 
Perspective_costs 
Direct Are direct costs listed/explicitly named? 0 no 
1 yes 
2 no, but discussed 
Direct_costs 
Indirect Are indirect costs listed/explicitly named? Indirect_costs 
Intangible Are intangible costs listed/explicitly named? Intangible_costs 
Intv costs 
overall 
Are the total costs of the intervention(s) named? (if no, 
study shouldn’t be included). Also valid for: eg costs of 
one HIV test/one person counselled / “one unit of inter-
vention” 
1 yes, and more details 
2 yes, but no more de-
tails 
costs_overall 
Type of 
costs 
Personnel costs (if overall only or personnel-related, detailed (such as: 
Salaries, travel, recruitment, training, food, quality assurance, …)) 
0 no 
1 yes 
Personnel_cost 
Material/equipment costs Material_cost 
Travel/transportation Travel_cost 
Overhead (eg rent, facilities, vehicles, administration, IT, telephone, 
…) Overhead_cost 
Other (eg start-up activities, child care (for participants), other nonpar-
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Monetary incentives Part_money 
Travel, transportation Part_travel 
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volunteer costs (if overall and/or detailed) 
0 no 
1 yes 
Volunt_overall 
Recruitment Volunt_recr 
Food Volunt_food 
incentives Volunt_incentives 
Travel, transportation Volunt_travel 
Data collection 
method(s): costs 
1 Primary data 
2 Secondary data 
3 both 
cost_data_collect 
 
Participant (time) costs. Methods? What kind 
(source) of data (eg budget data, )? string part_data_source 
Volunteers (time) costs. Methods? What kind 
(source) of data (eg budget data, )? string Volunt_data_source 
Other costs (eg personnel), also indica-
tors/parameters used, … String Other_cost_source 
Time frame* ..to which cost data refer: Start Year YYYY cost_tf_start ..to which cost data refer: End Year YYYY cost_tf_end 
Discounting rate* x% (if no discounting: 98) [number] Cost_discounting 
Estimations Have the costs been estimated (eg based on other data)? 
0 no 
1 yes Cost_estimations 
Modelling 
Have the costs been modelled (eg 
based on other data)? 
 
0 no 
1 dynamisch 
2 nicht dynamisch 
3 yes, other 
cost_modelling 
*: 0 no information/unknown/not identifiable ; 99 unclear to coder 
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consequences Variable 
Monetarisierung 
Treatment costs 
0 no 
1 yes 
Treatcost_monet 
QALY QALY_monet 
DALY DALY_monet 
WTP WTP_monet 
Mortality/morbidity Mortmorb_monet 
Productivity gains Prodgain_monet 
Monetarisierung De-
tails 
‘how’? (eg mit welchem Wert? Woher stammt 
dieser Wert?) string Monet_how 
Data collection 
method(s): effects 
1 Primary data 
2 Secondary data 
3 both 
Eff_Data_collect 
source of secondary data? (Wie erhoben? 
Inzidenz-/ Prävalenzdaten? ) string Eff_Data_source 
Time frame* 
..to which effect data refer: Start Year YYYY eff_data_tf_start 
..to which effect data refer: End Year YYYY eff_data_tf_end 
Time period / dura-
tion of effects No time frame, but period/horizon (see prospective studies) Eff_data_tp 
Discounting Rate* x% (if no discounting: 98) eff_discounting 
Estimations 0 no / 1 yes  eff_estimations 
Modelling 
Have the effects been modelled 
(eg based on other data)? 
 
0 no 
1 dynamisch 
2 nicht dynamisch 
3 yes, other / unclear 
eff_modelling 
Sensitivity Analysis 
Performed? 0 no / 1 yes Sens_anal 
Approach used / range (eg of re base case 
/factors) string Sens_anal_approach 
Limitations men-
tioned re… 
Costs string cost_limit 
Effects string Eff_limit 
general string General_limit 
*: 0 no information/unknown/not identifiable ; 99 unclear to coder 
 
11.7  Studies included in the in-depth analysis, by axes 
Full references can be found in the bibliography of the 1st level analysis. 
Axis 1: Chesson (2006), Cohen et al. (2004, 2005), Farnham et al. (2012), Gillespie et al. (2012), Holtgrave/Kelly 
(1997), Holtgrave et al. (2012), Long et al. (2010), Mehta et al. (2002), Prabhu et al. (2011), Sanders et al. 
(2005), Varghese et al. (1999), Wang et al. (2000, 2002), Yazdanpanah  et al. (2010). 
Axis 2: Anderson et al. (2009), Cohen et al. (2004, 2005), Heumann et al. (2001), Holtgrave (2002), Juusola et al. 
(2011), Kahn et al. (2001), Long et al. (2010), Pinkerton et al. (1997, 1998), Pinkerton/Holtgrave (2000a), 
Prabhu et al. (2011), Sanders et al. (2005), Tao et al. (1998), Tuli et al. (2009), Yazdanpanah et al. (2010). 
Axis 3: Cohen et al. (2004, 2005), Lee et al. (2005), Marseille et al. (2011), Varghese et al. (1999). 
 
11.8  Data availability for the calculation of the social cost of HIV/STI 
Table is displayed on the following page. 
 
 Table 20: Data availability for the calculation of the social cost of HIV/STI (excluding intangible costs) 
 Data need Data availability Remarks 
Affected population Data on the lifetime treatment HIV 
Data on the treatment of other STI (complications, etc.) 
SHCS data 
Forthcoming estimation by P. Vernazza 
 
Missing / incomplete data: 
Data on STI treatment 
SHCS covers only HIV; representa-
tiveness is unclear (75% of HIV pa-
tients in ART) 
Treatment costs Inpatient care 
Frequency and duration of inpatient care, average value 
per case 
− Hospital care 
− Institutional psycho-social care 
SHCS data 
FSO Swiss hospitalisation statistics, (diagnoses, DRG / APDRG); Swiss in-
stitutional psycho-social care statistic,  
FOPH act-info statistic of addiction assistance  
Zurn et al. 2001 
 
Missing / incomplete data: 
Institutional psycho-social care (estimation by Zurn et al. 2001). 
Delimitation of HIV/STI related health 
problems from other health problems. 
 Outpatient care: 
Service frequency and duration of outpatient care, average 
value per case 
− Ambulatory medical visits HIV/STI 
− Psychotherapy; psychological problems related to HIV 
− Home care HIV 
SHCS data (Laboratory analyses, no data on medical visits) 
FSO costs for home care in general, not related to HIV 
Data of the health insurances (Data Warehouse CSS Group, santésuisse 
data pool, IMS) 
Auerbach/Früh 2012 
Zurn 2001 
 
Missing / incomplete data: 
Data for home care 
Data for psychotherapy (Zurn et al. 2001) 
Delimitation of HIV/STI related health 
problems from other health problems 
 Drugs (Antiretroviral drugs, co-morbidity drugs, co-
mediation, drugs to treat other STI) 
SHCS data (AR drugs, few other drugs) 
FSO Swiss hospitalisation statistics 
Drug sales/consumptions (e.g. Data Warehouse CSS Group, santésuisse 
data pool, IMS) 
Auerbach/Früh 2012, Zurn 2001. 
 
Morbidity costs Disability to work duration  
− Average working absenteeism per case, (frequency of 
permanent/temporal and full/partial disabilities) 
− Voluntary work and informal care per case (average 
time per case) 
SHCS data on working rate / income sources. 
FSO Swiss labour force survey, disability insurance statistics;  
Monetary assessment of voluntary work by the SFSO. 
 
Missing / incomplete data: 
Absenteeism  
Voluntary work and informal care per case (average time per case) 
SHCS covers HIV; representativeness 
is unclear 
Mortality costs premature death  SHCS data and analysis of life expectations of HIV patients 
FSO statistics of causes of death, including the number of lost life years. 
 
Completeness of SFOS causes of 
death statistics is disputed 
SHCS covers mainly HIV; representa-
tiveness is unclear 
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11.9  List of interviewees 
Name  Affiliation Date Interview con-
ducted by 
Urs Brügger Zürcher Hochschule für Angewandte Wis-
senschaften, Winterthurer Institut für Ge-
sundheitsökonomie (WIG) 
11.12.2012 K. Frey 
C. Goodman 
Rolf Iten Infras, Zürich  28.2.2013 K. Frey 
Sonia Pellegrini Obsan, Neuchâtel 14.12.2012 K. Frey 
C. Goodman 
Matthias Schwenkglenks Institut für Sozial- und Präventivmedizin 
Universität Zürich 
3.12.2012 K. Frey 
C. Goodman 
Harry Telser Polynomics, Olten 19.12.2012 K. Frey 
11.10  Interview guideline  
Interviews were conducted in German. Below you find the interview guideline in its original language. 
Leitfaden Experteninterviews 
Einleitung: 
Im Auftrag des Bundesamtes für Gesundheit (BAG) führen wir eine Vorstudie durch, in der wir die Machbarkeit 
einer ökonomischen Evaluation der HIV/STI-Prävention in der Schweiz analysieren. Diese Vorstudie soll Diskus-
sionsgrundlagen zur Konzeption einer realisierbaren ökonomischen Evaluation zur HIV/STI-Prävention bereitstel-
len.  
Im Rahmen der Vorstudie analysieren wir die internationale Literatur im Bereich der ökonomischen Evaluation zur 
HIV/STI-Prävention. Um den spezifischen Kontext der Schweiz zu berücksichtigen, führen wir Interviews mit Ex-
pertinnen und Experten der ökonomischen Evaluation im Gesundheitsbereich durch. Schliesslich umfasst diese 
Vorstudie auch eine Pilotstudie, so werden wir die Kosten (Input-Seite) für eine Präventionsmassnahme im Kan-
ton Zürich erheben (Mission possible). 
Im folgenden Gespräch möchten wir ihre Expertenmeinung zu einer ökonomischen Evaluation im Bereich der 
HIV/STI-Prävention abholen. Das Gespräch gliedert sich wie folgt: 
• Möglichkeiten einer ökonomischen Evaluation im Bereich HIV/STI-Prävention allgemein 
• Vorstellung des BAG über die ökonomische Evaluation der HIV/STI-Prävention 
• Ausgestaltung einer ökonomischen Evaluation der HIV/STI-Prävention 
 
1. Möglichkeiten einer ökonomischen Evaluation im Bereich HIV/STI-Prävention 
• Was sind die Möglichkeiten und Grenzen einer ökonomischen Evaluation im Bereich HIV/STI-Prävention? 
Beurteilung?  
Die ökonomische Evaluation kennt unterschiedliche Typen von Analysen. Meist wird zwischen Kosten-
Wirksamkeits-Analysen (cost-effectiveness/-consequences), Kosten-Nutzwert-Analysen (cost-utility) und Kosten-
Nutzen-Analysen (cost-benefit) unterschieden. 
• Wie beurteilen sie die Aussagekraft, Machbarkeit und Nutzen dieser Analysetypen (auch in Bezug auf allfälli-
ge Schwierigkeiten und Grenzen)? 
 
2. Beurteilung der BAG-Vorstellungen für eine ökonomische Evaluation im Bereich der Prävention von 
HIV und STI 
Gemäss BAG soll die ökonomische Evaluation eine gesellschaftliche Perspektive einnehmen. Das Kosten-
Nutzen-Verhältnis der HIV/STI-Prävention in der Schweiz soll insgesamt analysiert werden, aber auch das Kos-
ten-Nutzen-Verhältnis der einzelnen Interventionsachsen des neuen nationalen Programms aufzeigen (1: Ge-
samtbevölkerung; Interventionsachse 2: Personen mit einem erhöhten Expositionsrisiko; Interventionsachse 3: 
Infizierte Personen und deren Partnerinnen und Partner.). 
• Wie beurteilen Sie die Aussagekraft und Nutzen (Nutzung für die Politikformulierung) eines solchen Vorha-
bens? Grenzen?  
• Wie beurteilen Sie die Machbarkeit eines solchen Vorhabens? Schwierigkeiten 
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Diese Analyse soll einerseits alle Kosten (Input) berücksichtigen, andererseits auch für die BAG-
Präventionsanstrengungen (BAG-Ressourcen) separat durchgeführt werden. 
• Wie beurteilen Sie die Aussagekraft und Nutzen (Nutzung für die Politikformulierung) einer solchen Unter-
scheidung? Grenzen?  
• Wie beurteilen Sie die Machbarkeit einer solchen Unterscheidung? Schwierigkeiten 
Das BAG interessiert sich zudem für die optimale Verteilung der Präventionsmassnahmen (Ressourcen) auf die 
drei Interventionsachsen des NPHS: Welcher Mix produziert das beste Kosten-Nutzen-Verhältnis? 
• Wie beurteilen Sie die Aussagekraft und Nutzen (Nutzung für die Politikformulierung) einer solchen Analyse? 
Grenzen?  
• Wie beurteilen Sie die Machbarkeit einer solchen Analyse? Schwierigkeiten 
Das BAG interessiert sich schliesslich speziell für das Kosten-Nutzen-Verhältnis der Zürcher Präventionsmass-
nahmen für Männer, die Sex mit Männern haben (MSM). 
• Wie beurteilen Sie die Aussagekraft und Nutzen (Nutzung für die Politikformulierung) einer solchen Analyse? 
Grenzen?  
• Wie beurteilen Sie die Machbarkeit einer solchen Analyse? Schwierigkeiten 
 
Welche Perspektiven/Anliegen sollten Ihrer Meinung nach Priorität geniessen? Begründung? 
 
3. Ausgestaltung einer ökonomischen Evaluation der HIV/STI-Prävention  
Fragen zur Konzeption und Messung der Kosten (Input / Ressourceneinsatz) 
• Welches sind die Kostenarten, die bei einer ökonomischen Evaluation von HIV/STI-Präventionsmassnahmen 
auf der Input-Seite (zwingend) berücksichtigt werden sollten? 
• Welche Möglichkeiten sehen sie zur Erhebung der Kosten (Ressourceneinsatze) der HIV/STI-Prävention in 
der Schweiz? (Voll/Teilerhebung, Datenquellen, Schwierigkeiten). 
Fragen zur Konzeption und Messung der Konsequenzen der HIV/STI-Prävention  
• Welche Wirkungen und Nutzen der HIV/STI-Präventionsmassnahmen sollten in einer ökonomische Evaluation 
(zwingend) berücksichtigt werden? 
• Welche Ansätze zur Identifikation/Bewertung des Nutzen (Nutzwerte) eigenen sich für eine ökonomische Eva-
luation von HIV/STI-Präventionsmassnahmen?  
• Welche Möglichkeiten sehen sie zur Erhebung der Konsequenzen der HIV/STI-Prävention in der Schweiz? 
(Schwierigkeiten, Kausalitäten, Datenquellen, usw.) 
 
Ökonomische Evaluationen können unterschiedliche Zeitperspektiven einnehmen, d.h. retro- oder prospektive 
Aussagen generieren: 
• Welche Möglichkeiten sehen sie in Bezug auf die Zeitperspektive einer ökonomischen Evaluation von 
HIV/STI-Präventionsmassnahmen der Schweiz? 
− Retro- oder prospektiv? Begründung? (Aussagekraft, Machbarkeit, Nutzen für die Politikformulierung) 
− Angemessen Zeitperiode? Begründung? 
 
Diskontierung und Sensivitätsanalysen 
• Zu Beginn des Gesprächs haben wir über den Zeithorizont einer ökonomischen Evaluation gesprochen. Wie 
beurteilen sie die Frage der Diskontierung der Kosten im Rahmen einer ökonomischen Evaluation von 
HIV/SIT-Präventionsmassnahmen? 
• Welches sind die Möglichkeiten von Sensivitätsanalysen im Rahmen einer ökonomischen Evaluation der 
HIV/SIT-Prävention? (zwingende Parameter/Faktoren, Ansatz, Range) 
 
4. Weiterführende Hinweise 
• Gibt es (bedeutsame) Aspekte einer ökonomischen Evaluation der HIV/STI-Prävention, die wir im Rahmen 
dieses Gesprächs noch nicht angesprochen haben? 
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• Gibt es eine ökonomische Evaluation im Präventionsbereich, die sie uns als gutes Beispiel empfehlen möch-
ten? 
• Weitere mögliche Gesprächspartner/-innen: Welche Expertin oder welcher Experte könnte uns weitere wert-
volle Hinweise zu den Möglichkeiten einer ökonomischen Evaluation der HIV/SIT-Prävention liefern?  
 
